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 ABSTRACT: Densin-180 is one of the first discovered, most abundant and, yet, most obscure core 
components of the postsynaptic density, a specialised structure playing a key role in synaptic 
transmission of excitatory neurons in the central nervous system, a process fundamental to the 
learning and memory processes of the brain. A founding member of the LAP (Leucine-rich repeat 
and PDZ domain containing) protein family, it features 16 leucine-rich repeat domains, 2 LAP specific 
domains, a phosphorylation rich region and a PDZ domain, and has identified interactions with a 
number of PSD components which include CaMKII-α, α-actinin, Cav1.3 (L-type Ca2+) channels, 
MAGUIN-1, δ-catenin and Shank.  Densin-180 is thought to function as a key adapter protein, 
coordinating cytoskeletal, scaffolding and receptor molecules in the adaptation, maintenance and 
regulation of the highly dynamic cell to cell contacts that are synapses of the CNS. Here, we present 
9 eGFP-tagged Densin-180 fusion constructs for the detailed study of Densin-180’s function and 
show that C-terminal PDZ domain and C-terminal terminal amino acid mediated protein-protein 
interactions play a key role in Densin-180 punctate behaviour in HEK 293 TSA Cells.  
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Foreword 
Since the dawn of mankind, thinkers from all walks of the Earth have philosophised, questioning the 
nature and meaning of Life. 
Throughout history, human civilisations have created, celebrated and immortalised countless 
schools of thought; innumerable pieces of knowledge have been applied in infinite ways, shaping the 
culture and survival of past societies. 
Is there, or is there not a God, or many Gods? That’s a matter of opinion. Is there such a thing as 
chance, that probability of an event occurring, that entropy applicable to all physical matter in the 
universe? Definitely. Religion is arbitrary, but entropy is fundamental. 
Since its advent, the scientific method has broken many boundaries for the first time, ushering in the 
advance of new technologies through the investigation of natural phenomena, drawing on, 
correcting and adding to existing knowledge. As a direct consequence of the spring in scientific and 
technological advancement that has occurred to date, we live in an age of impressive sociocultural 
evolution, currently occurring at an unprecedented rate and scale. The world is changing, faster and 
faster. 
The advances incurred by the emerging mechanistic understanding of the brain will allow us to 
directly interfere with the fabric of the mind. 
 
“We saw that an exact knowledge of the structure of the brain was of 
supreme interest for the building up of a rational psychology. To know the 
brain, we said, is equivalent to ascertaining the material course of thought 
and will, to discovering the intimate history of life in its perpetual duel 
with external forces; a history summarized, and in a way engraved in the 
defensive neuronal coordinations of the reflex, of instinct, and of the 
association of ideas.” 
p305 Ramon y Cajal: Recollections of My Life. E. Horne Craigie.  
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Introduction 
Neuroscience, the synapse and its underlying machinery 
Until the emergence of modern neuroscience, history’s most influential thinkers have only been able 
to study the human mind based solely on non-invasive observations of human behaviour. An 
understanding comparable to an amateur understanding of how a modern car works based solely on 
observations of how it moves. 
Examples of contemporary developments spurred by modern neuroscience include:  
 powerful psychological models of employee motivation, bringing together research from 
neuroscience, biology, and evolutionary psychology [1];  
 potential stem cell therapies for neurological disorders, including Parkinson’s disease, 
Alzheimer’s disease and spinal cord injury  [2][3], and  
 brain-machine interface technology allowing people with spinal cord injury, brainstem 
stroke, and amyotrophic lateral sclerosis to control a computer cursor simply by thinking 
about the movement of their own paralyzed hand [4][5]. 
Molecular Neuroscience 
Molecular neuroscience combines modern molecular biology, traditional biochemistry and 
contemporary proteomics to, essentially, open up the brain, allowing us to take a peek under the 
hood, and gain mechanistic insight into the brain’s complex functioning. 
However, unlike the mechanics of a car, the mechanics of the brain are composed of lipid, protein, 
sugar and nucleic acid components, all arranged in a naturally evolved order. Therefore, the task of 
interpreting the arrangement of these components is more like interpreting a piece of contemporary 
art than it is like making sense of an engineering diagram. 
Synaptic transmission 
The principle unit of the nervous system is the neuron, whose function is to receive information 
from other cells via dendrites, to integrate this information and to transmit this information via its 
axon. The information is electric, caused by ion fluxes across the nerve cell membrane relying on 
gradients (Table 1-1), established by a panoply of ion transporters, and on a range of ion channels 
selectively permeable to these ions. The dendrites, soma and axon have varying membrane 
constituents and therefore appropriately varied electrical properties to suit their functions within 
the neuron. 
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Ion Intracellular Extracellular
Potassium (K+) 140 5
Sodium (Na+) 5-15 145
Chloride (Cl-) 4-30 110
Calcium (Ca2+) 0.0001 1-2
Concentration (mM)
 
Table 1-1. Extracellular and Intracellular Ion Concentrations in Mammalian Neuron. The gradients 
established by membrane spanning ion pumps and transporters mean that there is a potential 
charge across the plasma membrane of a neuron, like the voltage of a charged battery. Adapted 
from [6]. 
An action potential is triggered when the resting membrane potential of an axon (usually -70mV) is 
depolarised past a certain threshold, causing the activation of voltage gated Na+ channels. The influx 
of Na+ ions into the cell cause a rapid depolarisation lasting 0.5 to 1 ms, short-lasting due to the 
inactivation property of voltage gated Na+ channels and voltage gated K+ channels opening. The 
action potential therefore propagates unidirectionally along the axon in an all or none fashion (figure 
1-1). 
Since neurons do not touch, when the action potential reaches the axon terminal, the signal is 
transmitted via a chemical synapse (figure 1-2). When the action potential arrives here, the 
depolarisation activates voltage gated Ca2+ channels and the resulting influx of Ca2+ ions initiates the 
fusion of neurotransmitter containing vesicles to the presynaptic membrane, releasing 
neurotransmitter into the synaptic cleft. Neurotransmitter diffuses rapidly across the approximately 
20 nm wide synaptic cleft and is picked up by either neurotransmitter receptors, uptake or 
breakdown mechanisms, the latter two of which terminate the transmission. When picked up by 
neurotransmitter receptors, the neurotransmitter will elicit a response.  
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 Figure 1-1. The action potential. At t = 1, action potential arrives point A, depolarisation of the 
membrane causes opening of Na+ channels. The inward current flows passively onwards resulting 
from channel opening activates adjacent Na+ channels: action potential is now at point B. K+ channel 
opening and Na+ channel inactivation repolarise the membrane at point A. At t = 3, inward current 
spreads onwards from point B, action potential propagates to point C. The time course of the 
membrane potential at these points is illustrated in the bottom panel. Adapted from [6]. 
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Figure 1-2. Basic sequence of events of a typical synaptic transmission. Adapted from [6].  
Types of neurotransmitters and neurotransmitter receptors 
There are many neurotransmitters and many more neurotransmitter receptors, many identified 
using the patch clamp technique, which could measure single channel currents, and using modern 
molecular biology techniques, which allowed the identification and cloning of ion channels. CNS 
neurotransmitters include: amino acids, glutamate and γ-Amino-Butyric-Acid (GABA); 
catecholamines dopamine, noradrenaline, adrenaline; amines, 5-hydroxytryptamine, histamine and 
melatonin; purines, adenosine and adenosine 5’-triphosphate (ATP); gases, nitric oxide and carbon 
monoxide; lipids, arachidonic acid and Anandamide; peptides, β-endorphin, and many more 
established and being established. [7] 
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 Figure 1-3. Ionotropic and G-Protein Coupled Receptors. A) Diverse subunits assemble to form 
functioning ionotropic receptors, which have an extracellular transmitter binding sites and a gated, 
central ion permeable pore. B) G-Protein Coupled Receptors are monomeric and have 7 
transmembrane domains: neurotransmitter binding region is linked to domains II, III, VI and VII; G-
Protein binding domain is linked parts of C-terminal and to domains V and VI. Adapted from [6]. 
Due to the varied nature of neurotransmitters, their properties and modes of function are varied. 
For example, while a classical neurotransmitter such as glutamate functions in the classical manner 
described above, nitric oxide, an organic gas, diffuses rapidly across plasma membranes following 
synthesis by neuronal Nitric Oxide Synthase (nNOS) and activates soluble guanylate cyclase, which 
catalyses the conversion of GTP (guanosine triphosphate) to cGMP (3',5'-cyclic guanosine 
monophosphate), an intracellular second messenger, like cAMP, which drives adaptive and 
developmental changes.  
It is important to bear in mind that a neurotransmitter does not act on a single receptor. Nature has 
done away with the restrictions of such an arrangement and has evolved a large number of receptor 
types, each with a variety of configurations, devoted to each neurotransmitter.  
Neurotransmitter receptors are far more varied than the neurotransmitters themselves, and for 
classical neurotransmitters these fall into 2 main types: ionotropic, or ligand gated ion channels, 
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which increase membrane permeability to specific ions upon activation, and metabotropic, or G-
protein coupled receptors, which initiate intracellular signalling processes upon activation (figure 1-
3). All have subtypes.   
To illustrate neurotransmitter receptor variety, glutamate has 3 types of ionotropic receptors, 
NMDA (N-Methyl-D-aspartate) receptors, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic) 
receptors, Kainate receptors, as well as G-protein coupled receptors termed metabotropic 
glutamate receptors (mGluRs).  
NMDA receptors are composed of two NR1 and two NR2 subunits. The NR1 subunits are coded for 
by a single gene, but have eight functionally different splice variants (3 independent splice sites [8]). 
Four genes code for NR2A/B/C/D subunits. There are two NR3 subunits (NR3A and NR3B), which 
may coassemble with NR1/NR2 subunits to form triheteromeric receptors (different NR2 subunits 
may also dimerise to form triheteromeric receptors). NR2 and NR3 subunits have splice variants. 
Various subunit compositions make for varied receptor properties: in NMDA receptors single 
channel conduction properties (figure 1-4) and sensitivity to Mg2+ block depend on NR2 subunit 
composition; NR1 isoforms dictate receptor targeting to different membrane regions [9], the pH, 
polyamine and Zn2+ sensitivity, as well as deactivation properties of NMDA receptors [8].  
AMPA receptors are each composed of 4 subunits (GluR1, GluR2, GluR3 and GluR4), which assemble 
as dimers of dimers of GluR2 and either GluR1, GluR3 and GluR4, giving a total of 4 possible 
arrangements. Kainate receptors have five types of receptor subunits forming tetramers, and there 
are 5 possible arrangements, while there are 8 types of mGluRs (mGluR1 - 8), with further subtypes 
(e.g. mGluR7a and mGluR7b).  
With this degree of neurotransmitter receptor variety, the impact of presynaptic activity on 
postsynaptic activity can be varied.    
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Figure 1-4. NMDAR channel 
properties depend on NR2 
subunit composition. A) 
NMDAR single channel 
conductances: NR2A (cyan) 
and NR2B (green) channels 
have high conductances, 
while NR2C (orange) and 
NR2D (purple) have lower 
(but differing) conductances.  
B) NMDAR whole cell 
responses:  receptor time 
constants vary depending on 
subunit composition 
(NR2D>>NR2C=NR2B>NR2A)
. Figure adapted from [8]. 
  
Excitatory and inhibitory synapses 
A synapse can either be excitatory or inhibitory. In the CNS, glutamate is the neurotransmitter at the 
majority of excitatory synapses, while GABA is the neurotransmitter at the majority of inhibitory 
synapses. The reasons for glutamate’s excitatory nature and GABA’s inhibitory nature are their 
ionotropic receptors. These are positioned in the postsynaptic membrane in close proximity to the 
presynaptic membrane, and it is their permeability to specific ions when activated which may cause 
either a depolarisation or hyperpolarisation of the postsynaptic membrane, therefore promoting or 
attenuating postsynaptic excitability. What determines whether the postsynaptic response is 
excitation or inhibition is therefore the type of receptor that is activated, its ion permeability and the 
prevailing ionic gradients.  
Excitatory glutamatergic synapses are located, in their majority, on dendritic spines [10], are less 
than 1 µm wide [11], and have active zones visible in electron micrographs, termed PostSynaptic 
Densities (PSDs), where large amounts of cellular machinery are present, underlying biochemical 
signal transduction processes of the highly dynamic synapses. Located there, AMPA and NMDA 
receptors both have 4 ligand binding domains and have cation selective pores, yet the two receptor 
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types have very distinct roles, the former adapted towards rapid information transfer on a 
millisecond timescale and the latter towards information storage (figure 1-5).  
Figure 1-5. Time course of activation of AMPA and NMDA receptors are adapted to their functions. 
Adapted from [11].  
The four ligand binding sites of AMPA receptors require only two glutamate molecules to activate 
the channel, allowing for quick activation. The cation permeable pore selectivity depends on subunit 
composition: GluR1, GluR3 and GluR4 all display strong inwardly rectifying current voltage, due to 
polyamine pore block, and calcium permeability, whereas the GluR2 subunit removes calcium 
permeability and polyamine pore block [12]; most AMPA receptor channels in the CNS are not 
calcium permeable [13]. AMPA receptors have low binding affinity for glutamate, which means they 
stay activated for very short periods of time, allowing signalling on the millisecond timescale [12]. 
“Flip” and “Flop” GluR subunit splice variants change the receptor’s pharmacological and 
physiological properties, Q/R RNA editing of GluR2 subunits affect Ca2+ permeability and a host of 
TARPs (Transmembrane AMPA receptor Regulatory Proteins) serve as essential auxiliary subunits 
regulating AMPA receptors (TARPs).  
14 
NMDA receptors are ligand and voltage gated cation channels and act as coincidence detectors. 
These receptors have a number of interesting and unique features illustrated in figure 1-6.  
Figure 1-6. Cross section of NMDAR, 
showing NR1 subunit (right) and NR2 
subunit (left) in a dimer of dimer 
arrangement. Subunits have 3TM 
topology, both featuring an M2 re-
entrant pore loop, which determine pore 
permeability and voltage dependent Mg2+ 
pore block; large N- and C-termini, which 
have binding sites for extracellular 
ligands and intracellular proteins. Large 
N-termini have Venus-trap style 
glutamate and glycine binding sites are 
formed by S1 domain emerging from M1 
TM domain, and S2 loop, between M3 
and M4 TM domains. Other ligand 
binding sites are located on the N-termini 
of NR2 subunits (Zn2+ channel block 
through binding to LIVBP-like domain; Ifenprodil and polyamines). C-termini of NR1 and NR2 subunits 
have numerous binding sites for intracellular polyamines and to many postsynaptic proteins. Adapted 
from [8]. 
The fact that they can only be activated during periods of high activity which lift the Mg2+ pore block 
means that these receptors detect coinciding pre- and post-synaptic activity.  Their cation selective, 
Ca2+ permeable pores and currents lasting over 100 ms, mean that the activation of NMDA receptors 
is inextricably linked to Ca2+ homeostasis, and thus to synaptic plasticity, cell development, survival 
and excitotoxicity.  
Glutamate diffuses from the synaptic cleft into surrounding areas where high densities of Excitatory 
Amino Acid Transporters (EAATs) are positioned on surrounding Glial cells to rapidly transport 
glutamate, which diffuses from the synaptic cleft into surrounding area, ensuring rapid transmitter 
clearance and terminating the excitatory neurotransmitter signal in less than 1 ms [11]. EAATs are 
similar to ion channels, but carry out active transport coupled to the Na+ ion gradient.  
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The GABA ionophores (GABAa and GABAc receptors) are analogous, pentameric and their activation 
is coupled to binding of 2 agonist molecules at distinct binding sites [14], presumably (again in 
analogy to nAChRs, located subunit interface sites). A key difference, though, is that activation of 
GABA ionophores opens a Cl- and HCO3- permeable channel, in contrast to the cation selective pore 
of nAChRs; since the ratio of ion to HCO3-/Cl- is about 0.2-0.4 [15], the ion flux that occurs upon 
channel opening is dominated by Cl- ions, causing a membrane hyperpolarisation. 
GABA, like glutamate, is accompanied by its own complement of uptake pumps (GAT1-3, BGT-1).  
However, the similarities do not stop there, since GABA transmission has been observed to be 
excitatory in immature neurons [16] (figure 1-7), where KCC2, a K+/Cl- transporter, is not expressed, 
and where as a consequence there were more intracellular Cl- ions than extracellular. [17]  
It was demonstrated that GABA excitatory synapses formed prior to Glutamatergic synapses [16], 
and it is thought that this provides “a solution to the problem of how to excite developing neurons 
to promote growth and synapse formation while avoiding the potentially toxic effects of mismatch 
between GABA mediated inhibition and glutamatergic excitation” [18]. 
 
Figure 1-7. The NKCC1 co-transporter (first identified in 1998 by Zhang and Jackson) is expressed 
from immature stages of neuronal development, before the expression of the KCC2 co-transporter. 
The developmental shift in KCC2 expression changes intracellular Chloride concentrations, 
consequently regulating the nature of GABAaR currents. Adapted from [17]. 
It is worth noting that it is technically incorrect to call a neurotransmitter excitatory or inhibitory 
since some, like acetylcholine, have receptors with inhibitory and excitatory effects. However, since 
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glutamate and GABA receptors are excitatory and inhibitory, usually and respectively, this usage is 
frequent and convenient.  
Receptor interactions with intracellular PSD proteins 
Neurotransmitter receptors are part of a highly organised, dense and regulated protein complex 
known as the postsynaptic density (PSD). Recent proteomic profiling of mouse PSD preparations 
revealed 2159 unique proteins [19] with functional groups including: scaffolding molecules; kinases 
and phosphatases, which regulate protein function; G-proteins and their effectors, which compose 
intracellular functional cascades, and adhesion proteins. 
To illustrate, NMDA receptors interact with a number of PSD components, which include: α-actinin, 
calmodulin, Ca2+/calmodulin-dependent protein kinase II (CaMKII), PDZ-domain-containing proteins, 
Yotaio, Neurofilament-Long (NF-L) and AP-2 [8]. 
The arrangement and composition of the PSD will directly control submembranous receptor-binding 
sites that in turn determine receptor abundance within synapses [20].  
One of the best studied examples, PSD-95, is a Membrane-Associated GUanylate Kinase (MAGUK), a 
core PSD protein concentrated at glutamatergic synapses and a prototypical PDZ (Psd-95/Drosophila 
Discs Large/Zona Occludens-1) protein. It acts as a postsynaptic scaffolding molecule, associating 
with other PSD proteins such as GKAP and Shank, anchoring NMDA receptors and associated 
signalling complexes, that regulate synaptic plasticity, to synapses.[21][22][23]  
PSD proteins can also directly regulate receptor function, as is the case with CaMKII-α, a 
dodecameric holoenzyme, a core PSD component [24] and one of the most abundant CNS proteins 
[25]. CaMKII-α phosphorylates AMPA receptor GluR1 subunits on Ser831 residues, potentiating 
channel currents [26], and NMDA receptor NR2B subunits on Ser1303 residues [27], providing a way 
in which the function of these receptors can be modified rapidly upon Ca2+ influx following NMDA 
receptor activation. CaMKII-α function itself has been shown to be regulated in an activity 
dependent manner, via autophosphorylation on residue T286, in the enzyme’s regulatory region, 
occurring in an intraholoenzyme, intersubunit manner [28], which disrupts binding of its inhibitory 
pseudosubstrate region to its catalytic domain, rendering its activity autonomous of Ca2+ 
concentrations and allowing binding of the T286 site to NR2B subunit residues resulting in anchoring 
of enzyme complexes to specific synapses [29]. CaMKII-α has been shown to translocate to the PSD 
following NMDA receptor activation mediated Ca2+ influx [30].  
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Synaptic plasticity  
The strength of signal transmission between pre- and postsynaptic neurons relies on the 
coordinated function of the PSD’s molecular constituents, which can be regulated in a number of 
ways: changes in protein levels through local synthesis and degradation; reversible post-translational 
modification of the proteins themselves, such as phosphorylation and O-GlcNAc glycosylation, and 
changes in protein localisation. In synergy, these processes, underlying the long term changes in 
synaptic efficacy, are fundamental to higher cognitive processes such as learning and memory. 
There are many types of synaptic plasticity, which may be short-term or long-term and can be 
mediated pre-synaptically or post-synaptically, all occurring simultaneously.  
Short term plasticity  
This type of plasticity occurs in the millisecond to minutes timescale, influences the information 
processing function of synapses, allowing them to act as high- or low- pass filters.  
Paired-pulse facilitation 
Paired-pulse facilitation is when 2 stimuli are delivered within a short interval of each other and 
where the second stimulus is either enhanced relative to the first [31], or depressed. If the interval is 
less than 20 ms, depression occurs because of the inactivation of presynaptic voltage gated N-type 
calcium channels, but also transient depression of release-ready pool of vesicles docked at 
presynaptic terminal. With a longer interval of 20 to 500 ms, facilitation occurs because of residual 
intracellular Ca2+ from the stimulation contributing to neurotransmitter release during the second 
stimulation. However, whether facilitation or depression occurs also depends on the synapse’s 
activation history such that synapses that start with a high transmitter release probability are likely 
to depress their response to the second pulse and vice versa. [32]  
Facilitation and depression following trains of stimuli 
Facilitation and depression with longer timescales occurs in response to trains of stimuli. 
Augmentation is enhancement in neurotransmitter release lasting seconds, and Post-Tetanic 
Potentiation (PTP) is the same but lasting several minutes. Enhancement in neurotransmitter release 
in both is due to Ca2+ presynaptic influx in response to new stimuli coupled with residual presynaptic 
Ca2+ from previous stimuli.  
In synapses that start with a high neurotransmitter release probability, however, depression occurs 
due to: the depletion of the release-ready pool of neurotransmitter vesicles; the release of 
neuromodulatory substances from cells in the vicinity including the presynaptic terminal and 
postsynaptic cells, initiating signalling cascades that lead to the inhibition of presynaptic release 
machinery; and due to the desensitisation of postsynaptic ligand gated receptors, making target 
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neurons less sensitive to neurotransmitter. Since glia play an important part in neurotransmitter 
clearance, mechanisms modulating the speed and extent of neurotransmitter reuptake can also 
modulate synaptic transmission.  
Long Term Plasticity: Long Term Potentiation and Long Term Depression 
Long Term Potentiation (LTP) is a type of synaptic plasticity lasting hours to days, studied in 
hippocampal CA1 slices, which displays the following properties: cooperativity, since LTP can be 
induced by coincident activation of a critical number of synapses, allowing the activation of 
postsynaptic NMDA receptors; associativity: since a weak input can be potentiated when coupled to 
a strong input, a property of Hebbian synapses, which could underly classical conditioning, and input 
specificity, since LTP occurs only at activated synapses. This means each synapse can encode 
individual bits of information.  
 
Figure 1-8. LTP triggered by NMDAR at hippocampal CA1 synapses. Left panel: High-frequency 
tetanic stimulation triggers LTP. Initial slope of the field excitatory postsynaptic potential (fEPSP; 
normalised to baseline) defines synaptic strength. Right panel: schema illustrating typical electrode 
placement for studying LTP using rodent hippocampal slice preparation, showing the CA1, CA3 
regions, Dentate Gyrus (DG), Schaffer Collaterals (SC), Mossy Fibers (MF), Stimulating electrode 
(Stim) and Recording electrode (Rec). Adapted from [34]. 
Following activation of NMDA receptors, which requires strong postsynaptic depolarisation coupled 
with presynaptic neurotransmitter release, usually achieved experimentally by applying high 
frequency tetanic stimulation, the influx of Ca2+ into the postsynaptic terminal activates a number of 
kinases which induces signalling cascades resulting in the increase of AMPA receptors at the active 
PSD, and, thus, in an increased postsynaptic response to presynaptic activity (figure 1-8).  
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A very complex biochemical machinery is involved in the process, which involves  recycling 
endosomes containing reserve pools of AMPA receptors being mobilised and exocytosed at 
perisynaptic sites from which the receptors laterally diffuse to the PSD where they are anchored by 
MAGUKs, such as PSD-95, TARPs and others. Although a number of kinases are involved, CaMKII-α, 
and its special autophosphorylation property, play a key role in mediating LTP, since it has been 
shown to be impossible to induce LTP in knock-in mice in which the endogenous enzyme was 
replaced with a form lacking the autophosphorylation sites [33].  
Long Term Depression (LTD) is a decrease in postsynaptic response lasting hours to days. A smaller 
stimulation than used to induce LTP, causing smaller activation of NMDA receptors, causes an 
increase in postsynaptic Ca2+ small enough to activate protein phosphatases in preference to 
kinases. The function of protein phosphatases is to remove phosphorylation groups from proteins, 
and therefore to undo the work of kinases, and this leads to dissociation of AMPA receptors from 
PSD scaffolds and their subsequent internalisation. As with LTP, the mechanisms involved are both 
numerous and complex.  
Activation of mGluR1 receptors, located extrasynaptically, may also trigger LTD. These activated 
receptors induce phosphoinositide hydrolysis and diacylglycerol and inositol triphosphate 
production: second messengers that activate signalling cascades leading to changes associated with 
LTD. [34] 
LTD may also be initiated by a very different mechanism via endocannabinoids (termed 
Endocannabinoid Mediated LTD, or EM-LTD), whereby the retrograde messenger is released in 
response to strong postsynaptic depolarisation or activation of postsynaptic G-protein coupled 
receptors (such as mGluRs), and act via presynaptic CB1 receptors to inhibit neurotransmitter 
release. [33] 
In both LTP and LTD, rapid morphological changes to dendritic spines in response to activity are 
involved, and can include the growth of new spines, the enlargement of existing spines, the splitting 
of a single spine into two, and the opposite of these, highlighting how form and function go hand in 
hand in the CNS. [35] 
The occurrence of LTP and LTD mean that synaptic activity can bi-directionally control synaptic 
strength, and since there are 1011 neurons in the CNS, each with approximately 7000 synapses, these 
processes underly a huge memory storage capacity.  
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Other forms of plasticity 
Other, longer term forms of plasticity exist such as metaplasticity and synaptic scaling. Metaplasticity 
is the changes in the capacity of synapses to express long term plasticity, and synaptic scaling, a form 
of homeostatic plasticity, is when the strength of all synapses on a given neuron adjust in response 
to a prolonged change in activity. These forms of plasticity may exist to regulate shorter term 
plasticity in neurons, and to maintain the integrity of inter-neuronal circuitry within the CNS. [34]  
Densin-180 
Densin-180 is one of the first discovered, most abundant and, yet, most obscure constituents of the 
PSD: today a PubMed search for Densin-180 only reveals 23 publications.  
It was identified in the mid-90s as a core PSD protein in rat by the Kennedy lab in Caltech, along with 
PSD-95, CaMKII- and the NR2B NMDA receptor subunit. These core PSD proteins are all highly 
enriched (10 to 30 fold) in PSD fractions prepared by successive extraction with detergents, and 
remain associated with the PSD fraction even after extraction with N-lauroyl sarcosinate, a relatively 
harsh detergent. [37] 
Structure and domains 
The first mammalian member of the LAP (Leucine-rich-repeats and PDZ-domain containing) protein 
family, Densin-180, has 16 LRRs (Leucine rich repeats) located within its 400 N-terminal amino acid 
residues, and a PDZ (PSD95/Dlg1/ZO-1) domain located within its 100 C-terminal amino acid 
residues. In addition, there are two LAPSDs (LAP Specific Domain) situated between the LRRs and 
PDZ domains, which, although their function is currently unknown, have been used for the 
phylogenic analysis of LAP proteins: LAPSDa, a 38 amino acid LRR-like domain signature for the LAP 
protein family closely flanking the LRR region from the C-terminus; LAPSDb, a 24 amino acid motif, 
also conserved in LAP proteins, yet unrelated to LRR motifs, and a 42 amino acid spacer region 
between the two, which is folded in a putative -helix. This is illustrated in figure 1-9 below. 
[38][39][40] 
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Figure 1-9. Densin-180 and its domains. Domains from the N-terminus to the C-terminus: Cys14/16 
palmitoylation site (zigzag), LRRs (red) with putative structure shown (top left), LAPSDa and LAPSDb 
(purple), phosphorylation rich region (blue) and PDZ domain (green) with typical structure shown 
(top right). Adapted from [38]. 
The Densin-180 amino acid sequence is highly conserved across species, with mouse and rat 
sequences sharing 99% identity, and mouse and human sequences sharing 92% identity. The 
secondary, tertiary and quaternary structures of Densin-180, as well as its function, are therefore 
likely to be highly conserved across these species.  
Phosphorylation sites and the phosphorylation-rich region 
Recent phosphoproteomic analysis of the in vivo phosphorylation state of Densin-180 from tryptic 
digests of murine PSD preparations by tandem mass spectrometry using stringent statistical 
interpretation criteria, combined with manual inspection of the individual spectra, across multiple 
experiments and several independent sites, has identified a number of phosphorylation sites on the 
Densin-180 amino acid sequence (figure 1-10), and presents strong evidence for a phosphorylation-
rich region between amino acid residues 826 and 1213. This phosphorylation-rich area is highly 
conserved between species, with 99% amino acid sequence identity shared between rat and mouse, 
and 90% between rat and human. [38] 
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Site/region Peptide (refs a, c)
S826 T.IVGVPLELEQSTHR.H
S850 R.TPSPFEDR.T
T865 K.LETTPTTSPLPERK.D
T867-869 K.LETTP(TTS)PLPER.K
S933 K.STERLSPLmK.D
S949 K.SQSDEIDVGTYK.V
S1118 R.RADSLASSTEmAmFR.R
S1132 R.RVSEPHELPPGDR.Y
Y1205 not stated
Y1210 not stated
S1204-S1213 R.(SYSTESYGAS)QTRPVSARPTmAALLEK.I
S1392 R.SmDGYPEQFCVR.I  
Figure 1-10. Sequence (top) and table (bottom) displaying in vivo phosphorylation sites of murine 
Densin-180 (Q80TE7-1). Top: Putative Transmembrane Domain (TMD) is shown relative to 
phosphorylation sites. Bottom: phosphorylation sites and regions are shown in bold, ambiguity is 
shown with brackets, and lower case “m” refers to oxidation of methionine. Adapted from [38].  
Post translational glycosylation modification  
Glycosylation is another form of post translational modification in which glycans are added to 
proteins. Glycans be can mono-, oligo- or polysaccharides; since glycans can vary in size, the glycan 
contribution to the resulting glycoconjugate can vary greatly, and may constitute a large part of the 
glycoconjugate. Because the types of glycan that can be added are various, and because each 
monosaccharide can theoretically generate either an α- or β- linkage to any of several positions on 
the group to which they are added to, there are different types of glycosylations which include:   
- N-linked glycans attached to a nitrogen of asparagine or arginine side chains 
- O-linked glycans attached to the hydroxyl oxygen of serine, threonine, tyrosine, 
hydroxylysine, or hydroxyproline side chains 
- Glypiation, the addition of GlycoPhosphatidyl Inositol (GPI) anchor that links the protein to 
lipids through glycan linkages, similar to isoprenylation and palmitoylation. [70] 
O-linked β-N-acetylglucosamine (O-GlcNAc) is a type of glycosylation, which is, unlike complex N- 
and O-linked glycosylation modifications, poised to take part in dynamic signalling responses. It 
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occurs when the monosaccharide N-acetylglucosamine is attached in a β-linkage to Serine or 
Threonine hydroxyl groups of proteins. Unlike enzymes responsible for complex glycosylation, which 
are located in the Golgi and endoplasmic reticulum, O-GlcNAc Transferase and O-GlcNAcase, which 
catalyse the addition and removal of the O-GlcNAc modification are found in the cytosol and nucleus 
of cells, and the proximity of these enzymes to substrate proteins allows for the rapid regulation of 
these through the post translational modification, as observed in T-cell responses, glucose 
metabolism and insulin signalling. O-GlcNAc appears as widespread as phosphorylation and is found 
in all eukaryotes studies, and just like phosphorylation, O-GlcNAc is likely to have protein and site-
specific influences on multiple molecular processes. [41] 
Pharmacological manipulation, using activators or inhibitors of kinases and phosphatases, of the 
phosphorylation state of a cell has been shown to affect the levels of O-GlcNAc modifications in 
different subcellular fractions in an analogous, yet reciprocal manner [71]. Although there is not yet 
a consensus motif for the modification, many O-GlcNAC sites are identical to phosphosites in a 
number of proteins, such as c-Myc, the oestrogen receptor and SV-40 large T-antigen. It is therefore 
possible that O-GlcNAc and Phosphorylation may have a Yin-Yang relationship, in which they act 
reciprocally, and that proteins exist in a variety of forms through these post translational 
modifications. [41]  
Intracellular or transmembrane?  
Upon its discovery, Densin-180 was found to be anchored in the membrane fraction of PSD 
preparations by a combination of lipid and protein interactions. A transmembrane domain, spanning 
amino acid residues 1223 and 1246, was speculated in analogy to GPIb, an LRR protein functioning 
as a platelet adhesion molecule, backed up, apparently, with evidence from a Kyle and Doolittle 
hydropathy plot. In the discussion, Apperson et al [37] further speculate that Densin-180 may also 
have an adhesive function, in this case linking pre- and post-synaptic membranes. However, in the 
same paper, it is observed that no hydrophobic signal sequence, expected in a transmembrane 
protein, was found, and that the immunocytochemical localisation of Densin-180 in dissociated 
hippocampal neurons appears to be solely postsynaptic.  
In the 2009 review, Thalhammer et al [38] show, using numerous bioinformatics methods, that the 
existence and evidence for this transmembrane domain is pure machination [38]. Interestingly, a 
hydrophobicity plot of the rat Densin-180 sequence using the Kyte-Doolittle method (the same 
method used by Apperson et al [37]) shows no evidence of a transmembrane domain: as illustrated 
in figure 1-11, a transmembrane domain stands out rather clearly as a peak, as for the example 
Glycoprotein G, but no such peak can be seen in the plot for Densin-180.   
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Furthermore, biotinylation of surface proteins in dissociated hippocampal neurons followed by their 
precipitation, via streptavidin beads, and immunoblotting failed to detect Densin-180 when free of 
association with N-Cadherin [42], supporting the case for Densin-180’s cytosolic localisation.  
 
Figure 1-11. Kyte and Doolittle hydropathy plots of rat Lrrc7 (top; Uniprot identifier P70587) and of 
Glycoprotein G (bottom; Uniprot identifier P04882). While Glycoprotein G shows a large peak in 
hydrophobicity indicative of a transmembrane region near the carboxy-terminus of the protein, there 
is no indication of such a feature in Densin-180. Window size: 21. Plot generated using 
http://fasta.bioch.virginia.edu/fasta_www2/fasta_www.cgi?rm=misc1. 
In their 2008 paper, Izawa et al [43] also showed that Densin-180 is palmitoylated. They 
demonstrated that in vivo palmitoylation, of Cysteine residues 14 and 16, and the presence of the 
full LRRs were requirements for the plasma membrane localisation of Erbin, suggesting that this 
localisation was therefore dependant on interactions with both the plasma membrane, via 
palmitoylated residues, and with cytosolic components, via LRR region. Densin-180 is a close 
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homologue of Erbin, also featuring Cysteines at residues 14 and 16, and, it is fair to assume that 
Densin-180’s intracellular localisation is also determined through similar mechanisms [43]. It is 
important here to note that palmitoylation is exclusively an intracellular phenomenon, furthering 
the case against the existence of Densin-180’s putative transmembrane domain.  
Considering the evidence presented above, the existence of a transmembrane domain on Densin-
180, as described in the original Apperson et al paper [37], is unlikely and Densin-180 is more 
probably an intracellular protein, natively localised to the plasma membrane through interactions 
with membrane and cytosolic components. 
Protein-protein interactions 
As illustrated in figure 1-9 and figure 1-12, the currently exposed interactions of Densin-180 portray 
the protein as a promiscuous player amongst key synaptic players, fitting with the original 
observation of the protein’s dense presence among core PSD proteins [37]. One must note, 
however, that published literature only exposes protein-protein interactions involving Densin-180’s 
C-terminus; no interactions involving Densin-180’s LRR region have been observed in the current 
literature. LRR regions are thought to act as a ligand-binding domain [44]; Densin-180’s LRR region 
has been found to be indispensable for the protein’s correct native targeting [43] and so the 
function of Densin-180’s LRR domain should not be overlooked in future research. 
 
Figure 1-12. Densin-180 interacts with 2 functional groups of PSD protein complexes: signal 
transduction proteins (blue) and proteins involved in the regulation of structure and morphology 
(green).  
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Identified interaction partners Interaction with Densin-180 Reference
CaMKII-α
Targeted to PSD by Densin-180; developmentally regulated expression of splice 
variants that can't do this may regulate this function.
[45]
CaMKII-α and α-actinin
Interaction via CaMKII-α association domain. Activity dependant: binding 
affinity increases with CaMKII T286 autophosphorylation. Densin-180 localises 
CaMKII-α holoenzymes (newly synthesised in dendrite in response to excitation 
in glutamatergic synapses)
[46]
Ternary complex: CaMKII interacts with NR2B, Densin-180 and α-actinin-2 [47]
Cav1.3 (L-type Ca
2+) channels
Calcium dependant facilitation of Cav1.3 channel current requiring association 
of active CaMKII with Densin-180 and direct association of Densin-180 with 
Cav1.3-alpha subunit C-terminal domain.
[48]
MAGUIN-1 Ternary complex: Densin-180 --- MAGUIN-1 --- PSD-95 [49]
δ-catenin Ternary complex: Densin-180 --- δ-catenin --- N-Cadherin. Densin-180 is cytosolic.
[42]
Shank
Densin-180 overexpression causes increased dendritic branching and loss of 
PSD-95 synaptic clusters; Shank inhibits this effect and targets Densin to PSD 
membrane; δ-catenin is involved in this pathway. 
[51]
β-catenin
Densin-180 associates with Catenin-Cadherin complex (and with Nephrin 
complex)
[53]
 
Table 1-2 (above). Densin-180 interaction partners. Table 2-3 (below).  
Identified interaction partners Function Reference
CaMKII-α
Core PSD component, one of the most abundant proteins in the CNS. 
Important in the mediation of LTP. 
[24][25][29]
α -actinin
Present in multiple cellular regions. Plays multiple key roles, including: linking 
cytoskeleton to many transmembrane proteins in a variety of junstions; 
regulating the activity of a variety of receptors; serving as a scaffold to connect 
the cytoskeleton to diverse signalling pathways. 
[64]
Cav1.3 (L-type Ca2+) channels
Expressed together with Cav1.2 in many tissues, serves a pacemaker function. 
In neurons, couples activity with transcription events; mediates LTP in 
amygdala and participates in the consolidation of fear memory. 
[61]
MAGUIN-1
A member of the MAGUK protein family, expressed in neurons and localised in 
cell body and neurites. Interacts with S-SCAM and PSD-95; may play an 
important role in assembling components of synaptic junctions. 
[65]
Shank
Interacts with many signalling and scaffolding PSD molecules via SH3, PDZ, long 
proline rich region and Sterile Alpha Motif domains. One of the most abundant 
binding partners of Homer in the PSD; together these are major determinants 
of size of synaptic spines and of the PSD. 
[66]
δ-catenin
Neuron specific Catenin, implicated in adhesion and dendritic branching. 
Important for normal cognitive development
[67]
β-catenin
Part of adherens junction protein complex. Necessary for creation and 
maintenance of epithelial cell layers by regulating cell growth and adhesion 
between cells. Achors actin cytoskeleton and involved in Wnt signalling. 
[68]
Other proteins
NR2B
Core PSD component, an NMDA receptor subunit which acts as binding site for 
glutamate. Receptors containing this subunit are deeply implicated in the 
induction of LTP. 
[8][9]
PSD-95
A member of the MAGUK protein family, a core PSD protein that acts as a 
postsynaptic scaffolding molecule, anchoring receptors and cytoskeletal 
elements at synapses. Associates with other PSD proteins, like GKAP and Shank, 
where it anchors NMDA receptor associated signalling complexes that regulate 
synaptic plasticity. 
[21][22][23]
N-Cadherin
Neuronal, Calcium-dependent adhesion protein. Transmembrane protein 
important in cell adhesion, that mediates presynaptic to postsynaptic adhesion 
and is necessary for the establishment of left-right asymmetry during 
gastrulation.
[69]
 
Table 1-3 (above). Function of interacting proteins 
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Identified interaction partners include: CaMKII-, -Actinin and NR2B (via CaMKII-), Cav1.3 (L-type 
Ca2+) channels, MAGUIN-1, Shank, PSD-95 (via Shank and MAGUIN-1), -Catenin, -Catenins and N-
Cadherin (via the Catenins). The nature and function of these interactions, detailed in tables 1-1 and 
1-2, portray Densin-180 as a key interactor in the midst of receptor proteins, scaffolding proteins 
and structural proteins.  
CaMKII-, -Actinin, NR2B and Cav1.3 
The direct interaction with CaMKII-, another core PSD protein, is most interesting, due to its 
established role in synaptic plasticity. Strack et al [45] were first to report this interaction: they 
found that Densin-180 binds CaMKII- stoichiometrically and with high affinity, non-competitively to 
the CaMKII---NR2B interaction. Testing developmentally regulated Densin-180 splice variants, they 
found that one, missing amino acid residues 1331 to 1404, does not bind CaMKII-α, showing that 
these residues must be of importance to CaMKII-α binding. [32P-Thr286]CaMKII-α bound Densin-180 
with a Kd of 150 to 250 nM, a Kd similar to that for the CaMKII-α – NR2B interaction; Scatchard plot 
analysis showed that the interaction between CaMKII-α and Densin-180 is a simple bimolecular 
event. Although NR2B only binds Thr286-CaMKII, it was also shown that Densin-180 also binds 
inactive CaMKII-α, suggesting that the interactions occur via different mechanisms and that there 
may be the formation of a ternary complex, consistent with a role for Densin-180 as a CaMKII-α 
targeting molecule. Furthermore, they showed that coexpression of a membrane targeted fusion 
protein containing these residues shifted CaMKII-α subcellular localisation, resulting in strong 
colocalisation, and suggest that Densin-180 constitutively targets CaMKII-α to PSD membranes. [45]  
A year later, Walikonis et al [46] found this interaction to specifically involve CaMKII-’s association 
domain and to be activity dependant (CaMKII- T286 autophosphorylation increased binding 
affinity), also finding that this interaction does not include CaMKII-holoenzymes including CaMKII-β 
and other isoforms. They found that this interaction involves Densin-180’s C-terminal half, 
supporting the hypothesis that amino acid residues 1331 to 1404 are important for the interaction. 
Both Strack et al [45] and Walikonis et al [46] found that Densin-180 is phosphorylated by CaMKII-α 
at Serine residue 1397, but suggest that more phosphorylation sites are present. Walikonis et al [46] 
add to the hypothesis presented by Strack et al [45], suggesting that CaMKII- holoenzyme, which is 
newly synthesised in the dendrites of active glutamatergic synapses, is targeted by Densin-180 to the 
PSD, and that this function is enhanced when CaMKII-α is in its auto-phosphorylated form and when 
Densin-180 is phosphorylated. This conforms with the roles played by other LAP proteins, which play 
essential roles in sorting membrane proteins, and in organising signalling and structural proteins at 
cellular junctions. They also found that Densin-180 and CaMKII- form a ternary complex with -
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actinin, a cytoskeletal bundling protein, involving Densin-180 PDZ domain interaction to α-actinin; a 
complex which was expanded in 2005 by Robison et al [47] to include the NR2B NMDA receptor 
subunit. [46][47] 
Earlier this year, Jenkins et al [48] reported a facilitation of Cav1.3 Ca2+ channel currents, requiring 
active CaMKII-, CaMKII-α association with Densin-180, Densin-180 association with the C-terminal 
domain of the Cav1.3 1 subunit and Ca2+, presenting a novel mechanism for the intensification of 
postsynaptic Ca2+ signals during high frequency signalling involving Densin-180. [48] 
MAGUIN-1 and PSD-95 
In 2002, an interaction between Densin-180 and MAGUIN-1 (Membrane-Associated GUanylate 
kinase INteracting protein-1) was discovered [49]. MAGUIN-1 was found to link Densin-180 to PSD-
95 [49], another core PSD protein discovered in the 1990s by the Kennedy group. PSD-95, a 
Membrane Associated GUanylate Kinase (MAGUK), heteromultimerises with another MAGUK, Dlg2, 
and the complex, with many interaction partners, forms an integral part of the PSD scaffold.  
-Catenin, N-Cadherin and Shank 
The interaction between -Catenin (aka NPRAP) and Densin-180 was reported in 2002, and the cell-
cell adhesion molecule, N-Cadherin, was also found to be associated with this complex [42]. 
This supports the idea that Densin-180 has an indirect role in the organisation of synaptic cell-to-cell 
junction: N-Cadherin has a transmembrane domain, is a known cell-cell adhesion protein that is 
regulated via the interaction with -Catenin; Cadherin-Catenin complexes are known in both pre- 
and postsynaptic locations.  
Furthermore, -Catenin has been linked to GSK-3, linking the protein to the Wnt signalling 
pathway. The proper expression of -Catenin is critical for normal brain function and its turnover is 
regulated via GSK-3 signalling: an important event influencing synaptic structures and dendritic 
morphogenesis. [50] 
Densin-180 was also found to interact with Shank proteins, prominent constituents of the PSD 
localised at the interface between membrane receptors and the actin cytoskeleton, believed to play 
a role in the functional and morphological maturation of spines, via a 2-point interaction, one of 
these involving Densin-180 amino acid residues 1125-1542 and Shank SH3 domain, and the other 
involving Densin-180 region immediately preceding the PDZ domain and the N-terminal part of 
Shank proline rich region (between Shank amino acid residues 318 and 451). Intriguingly, deletions 
from both the N-terminal and the C-terminal end of Densin-180 were found to gradually affect 
binding to Shank, highlighting a possible role for Densin-180’s LRR region in the interaction. [51] 
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In HEK cells, coexpression of Shank led to redirection of Densin-180 from plasma membrane to 
intracellular clusters. In cultured hippocampal neurons, overexpression of Densin-180 caused 
excessive dendritic branching and the loss of PSD-95 clusters at the PSD, which may be due either to 
a reduction of the amount of dendritic PSD-95 or to a diffusion of the localisation of PSD-95; 
coexpression of Shank3 reversed this effect, abrogating branch formation, and retargeted Densin-
180 away from the PSD and plasma membrane, and blocked the interaction between -Catenin and 
Densin-180, leading to the suggestion that Shank changes the overall conformation of Densin-180 
such that the N-terminal part may no longer target the protein to the membrane. This supports 
Densin-180’s postsynaptic, intracellular localisation and the protein’s role in the regulation of 
synaptic and dendritic spine morphology. [51] 
Densin-180 in other tissues 
In the kidney, a systematic search by Ahola et al [52] for Nephrin-associated molecules, involving the 
precipitation of glomerular lysates with anti-Nephrin antibody and MALDI-TOF-MS analysis, 
identified Densin-180 outside the CNS for the first time. Interestingly, 2 molecular weights were 
observed: 185 kDa, as with previously identified Densin-180, in human podocyte lysates, and, more 
predominantly, 210 kDa in human glomerular lysates, highlighting the importance of post-
translational modifications in fine tuning the protein’s function. Electron microscopy found that 
Densin-180 localised at the slit diaphragms of glomerular podocytes, an important structure thought 
to be involved in glomerular filtration: a vital function. [52] 
Heikkilӓ et al [53] confirmed this in their 2007 paper, in which they report an interaction between 
Densin, P-cadherin and β-Catenin in kidney glomerular lysates, and find colocalisation of Densin, β-
Catenin, and F-Actin in the cell-to-cell contacts of cultured mouse podocytes; they propose that 
Densin may be involved in the formation of cell-to-cell contacts, including slit diaphragms. [53] 
Interestingly, Densin was also found at another vital junction, in the Sertoli cells of the testes. Sertoli 
cells are responsible for establishing and maintaining the spermatogonial stem cell niche, binding 
spermatogonial cells via N-Cadherins and carbohydrate residues. Densin was found colocalised with 
β-Catenin and N-Cadherin at the junction between Sertoli cells and spermatogonial cells, a junction 
that undergoes extensive restructuring during the process of spermatogenesis. [54] 
Much like dendritic spines and glomerular podocytes, Sertoli cells form foot-shaped structures; in 
line with Densin-180’s likely role in dendritic spines, it is thought that Densin-180 plays a similar role 
in these locations, maintaining cytoarchitecture and connections to the cytoskeleton at these vital 
junctions, via similar interactions and mechanisms.   
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Other LAP proteins 
Since the discovery of Densin-180, other LAP proteins have been identified, which led to the 
definition of the LAP protein family, which are classified according to the number of PDZ domains 
they carry. Examples include Scribble, Erbin and Lano.  
Of these, Erbin is Densin-180’s closest relative, sharing 69% of its amino acid sequence identity (see 
appendix section for protein alignments); the two proteins, carrying 1 PDZ domain, define the LAP1 
subfamilly of proteins and with 59 hits on Pubmed, Erbin is also Densin-180’s better characterised 
relative.  
First reported in the 2000 paper by Borg et al [55], Erbin was identified interacting with Receptor 
Tyrosine Kinase (RTK): ErbB2/HER2, an orphan receptor, activated by heterodimerisation with other 
RTKs such as EGFR and involved in morphogenesis and oncogenesis. Erbin was found to act as an 
adapter protein binding directly and specifically via its PDZ domain to ERBB2/HER2; mutations to 
Erbin binding site led to mislocalisation of the ERBB2/HER2 receptor [55]. 
An interesting example of Erbin’s involvement in ErbB receptor mediated signalling is outlined in a 
2009 paper, in which Tao et al [56] demonstrate the necessity of Erbin in NRG1 signalling (via the Akt 
intracellular pathway) and how this effects myelination in the peripheral nervous system. In Erbin-
null mice, they observed hypomyelination of myelinated axons and abnormal ensheathing of 
unmyelinated axons in Remak bundles, as well as an increased number of axons per Remak bundle, 
causing decreased nerve conduction velocity and increased sensory threshold to mechanical 
stimulation (Remak bundles occur when Schwann cells group together unmyelinated axons from 
multiple neurons, ensheathing them in a way that prevents any of the axons from touching). They 
were able to reproduce these effects in mice expressing mutant Erbin, lacking the PDZ domain, 
which is important in mediating the interaction between Erbin and ErbB2. They observed a reduction 
of ErbB2 protein in the sciatic nerves of mice expressing this mutant Erbin and demonstrated that 
the ErbB2 receptor becomes unstable, compromising NRG1 signalling, when Erbin expression was 
suppressed. They suggest that Erbin binds to, via its PDZ domain, and stabilises ErbB2 receptors in 
mouse sciatic nerves, a process that is necessary for NRG1 signalling. [56] 
Erbin was also implicated in the MAP Kinase pathway by Huang et al [57], who show that the protein 
hinders Raf activation through an interaction between Erbin and active Ras, which inhibits the 
interaction between active Ras and Raf. They showed that Erbin overexpression leads to inhibition of 
NGF-induced neuronal differentiation of PC12 cells, while downregulation of Erbin caused the 
opposite effect, potentiating NGF-induced neuronal differentiation of these cells. [57] 
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The parallels between Densin-180 and Erbin are many, as can be seen in table 1-4, a comparison of 
their domain sequence identities.  
Domain % Identity
LRR rich 70
LAPSDa 71
LAPSDb 79
Spacer region between LAPSD 
motifs
54
Phosphorich region 27
PDZ domain 72
Total 69  
Table 1-4. Densin-180 vs Erbin: domain homology 
Densin-180 and Erbin are close homologues, sharing 69% amino acid sequence identity. Since 
Densin-180 and Erbin have the same complement of identified domains, with a high degree of amino 
acid sequence identity across these, it is likely that Densin-180, like Erbin, is adapted to function as 
an anchor protein for receptor complexes and may even have a role in cell signalling events.  
As reviewed above, the N-terminal end, with its LRR region, is thought to act as a ligand binding 
domain, conferring localisation to specialised lipid microdomains in the plasma membrane, while the 
C-terminal end, with its PDZ domain, mediates protein-protein interactions with a number of 
proteins.  
The major differences between the two proteins are Densin-180’s phosphorylation rich region and, 
to a lesser extent, the spacer region between LAPSD motifs. The phosphorylation rich region may 
underlie differences in how Densin-180 interacts with kinases and other proteins and how these 
interactions are regulated, while the spacer region, being longer in Densin-180 than in Erbin, may 
affect the tertiary structure of Densin-180, adding flexibility to its N-terminal end, and may underly 
differences in how Densin-180’s LRR region may interact with proteins 
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In this thesis 
In order to study the subcellular localisation and behaviour of Densin-180, eGFP-tagged fusion 
constructs were designed and generated, allowing live imaging and convenient antibody tagging 
when expressed in cells. Phospho-null, phosphorylation rich region truncation and PDZ domain / C-
terminal amino acid deletion variants of the eGFP-tagged Densin-180 fusion constructs were also 
generated.  The eGFP-tagged Densin-180 fusion constructs come in two flavours (figure 1-13):  
 N-terminally eGFP-tagged Densin-180, pRK7a-N-eGFP-hLrrc7-WT, in which an eGFP tag is 
introduced between the Cys 14/16 and LRR sequences, so as to minimise any effect that the 
introduction of the tag may have on the function of either of these features. 
 C-terminally eGFP-tagged Densin-180, pRK7a-hLrrc7-eGFP-C-WT, in which an eGFP tag is 
introduced at the end of the Densin-180 sequence.  
Since the eGFP tag, comprised of 238 amino acid residues, is a rather large tag, it can be expected 
that its introduction into Densin-180 may alter the normal functioning of the protein. By introducing 
the tag in either the N-terminus or the C-terminus, any alterations to the protein’s behaviour or 
function will allow extrapolations to be made with regards to the characterisation of the protein’s 
features and domains.  
For the detailed study of Densin-180’s C-terminus, which is known to be involved in a number of 
protein-protein interactions, 3 deletion constructs were also designed and generated (figure 1-13):  
 pRK7a-N-eGFP-hLrrc7-PDZ-A, N-terminally eGFP-tagged Densin-180 missing the entire PDZ 
domain except for its last 3 terminal amino acids residues, 
 pRK7a-N-eGFP-hLrrc7-PDZ-B, N-terminally eGFP-tagged Densin-180 missing the entire PDZ 
domain and the very C-terminal amino acids, 
 pRK7a-N-eGFP-hLrrc7-PDZ-C, N-terminally eGFP-tagged Densin-180 missing the very C-
terminal 3 amino acids.  
Any effect caused by the introduction of the C-terminal eGFP-tag is likely to be caused by a 
disruption of function linked to the amino acids most closely neighbouring the tag; PDZ domains are 
known to bind selected peptides with hydrophobic residues at their C-termini and have unique 
optimal binding motifs specific to their types. These deletion constructs are designed to study the 
importance of Densin-180’s C-terminal amino acid residues, should they be acting as PDZ-domain 
ligands, and of its PDZ domain.  
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Further, to elucidate the function of Densin-180’s phosphorylation rich region, amino acid residues 
826 to 1213, which may be fundamental in Densin-180’s unique role in the PSD, since it represents, 
as mentioned above, the major structural difference between Densin-180 and Erbin, its closest 
homologue, as well as an area in which regulation of Densin-180 may occur. Of the phosphorylation 
sites discovered to date, the sites at residues T865, T868 and T869 were chosen because these 
together constitute the highest density of phosphorylation sites within the phosphorylation region. 
What’s more, inserting phosphorylation-null mutations knocking out all three sites could be done 
using a single pair of primers. The following 4 constructs were designed and generated (figure 1-14 
and 1-15):  
 N-terminally eGFP-tagged TTT865/868/869AAA triple phospho-null Densin-180, pRK7a-N-
eGFP-hLrrc7-TTT865/868/869AAA, 
 C-terminally eGFP-tagged TTT865/868/869AAA triple phospho-null Densin-180, pRK7a-
hLrrc7-eGFP-C-TTT865/868/869AAA, 
 N-terminally eGFP-tagged phosphorylation rich region truncated Densin-180, pRK7a-N-eGFP-
hLrrc7-nophosphorich, in which amino acids 702 to 1422 are removed, 
 C-terminally eGFP-tagged phosphorylation rich region truncated Densin-180, pRK7a-hLrrc7-
eGFP-C-nophosphorich, in which amino acids 702 to 1422 are removed. 
Densin-180 appears to function as a key adapter protein, coordinating cytoskeletal, scaffolding and 
receptor molecules in the adaptation, maintenance and regulation of highly dynamic cell to cell 
contacts in the synapses of the CNS, and in the kidney and testis of the periphery, yet its function 
remains obscure.  
Here we present constructs allowing for the functional characterisation of Densin-180 and of its 
specific domains. We also present observations and data from HEK cell expression studies of these 
constructs showing that Densin-180’s N-terminal Cys 14/16 residues and LRR region may be of 
importance for its membrane localisation and that its PDZ domain and very C-terminal amino acid 
residues play key roles in protein-protein interactions. We also show that CaMKII-α has a targeting 
effect, altering Densin-180’s subcellular localisation, an effect dependant on Densin-180’s C-terminal 
region. 
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Figure 1-13 (following page). Top: N-terminally eGFP-tagged Densin-180, pRK7a-N-eGFP-hLrrc7-WT, 
in which an eGFP tag is introduced between the Cys 14/16 and LRR sequences. Middle: C-terminally 
eGFP-tagged Densin-180, pRK7a-hLrrc7-eGFP-C-WT.  Bottom: N-terminally eGFP tagged C-terminal 
and PDZ Domain deletion construction: pRK7a-N-eGFP-hLrrc7-PDZ-A, pRK7a-N-eGFP-hLrrc7-PDZ-B, 
pRK7a-N-eGFP-hLrrc7-PDZ-C, with deletions detailed in the box.  
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Figure 1-14. Top: N-terminally eGFP-tagged TTT865/868/869AAA triple phospho-null Densin-180, 
pRK7a-N-eGFP-hLrrc7-TTT865/868/869AAA. Bottom: C-terminally eGFP-tagged TTT865/868/869AAA 
triple phospho-null Densin-180, pRK7a-hLrrc7-eGFP-C-TTT865/868/869AAA. 
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Figure 1-15. N-terminally eGFP-tagged phosphorylation rich region truncated Densin-180, pRK7a-N-
eGFP-hLrrc7-nophosphorich (top), C-terminally eGFP-tagged phosphorylation rich region truncated 
Densin-180, pRK7a-hLrrc7-eGFP-C-nophosphorich (bottom). In both, amino acid residues 702 to 1422 
are truncated, effectively truncating the phosphorylation rich region between amino acid residues 
826 to 1213. 
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Materials and methods 
Materials 
Chemicals 
All chemicals were purchased from Sigma-Aldrich [St Louis, Missouri, USA], Invitrogen [Carlsbad, CA, 
USA], Merck [Whitehouse Station, New Jersey, USA] or VWR [West Chester, PA, USA]. Cell culture 
media, sera and buffers were purchased from Invitrogen, culture dishes and tubes from Nunc 
[Roskilde, Denmark] and BD labware [Franklin Lakes, NJ USA]. Milli-Q [Millipore, Billerica, 
Massachusetts, USA] purified water was used throughout. Oligonucleotides were purchased from 
Sigma-Aldrich and diluted in TE or H2O to 100 µM stocks.  
Standards and buffers 
Methods 
Standard Molecular Biology techniques 
Bacterial cultures 
DH5- cells were streaked onto LB-agar plates and incubated overnight at 37C to obtain single 
colonies. Single colonies were picked and used to inoculate 2 ml Terrific Broth (TB) medium cultures, 
which were incubated overnight at 37C with vigorous shaking (250 rpm). For selection, 100 µg.ml-1 
Ampicillin was added to culture media. 
Minipreparation of plasmid DNA 
1.5 ml of TB medium overnight culture was centrifuged for 30 seconds at 10,000 rpm on a Centrifuge 
5415C [Eppendorf, Hamburg, Germany], supernatant removed by careful suction and cell pellet 
resuspended on ice in 150 µl of miniprep solution I (50 mM glucose, 20 mM Tris-HCl (pH 8.0), 2.5 
mM EDTA (pH 8.0)). 300 µl of freshly prepared miniprep solution II (100 mM NaOH, 1% SDS in H2O) 
was then added and samples were mixed vigorously and incubated on ice for 5 mins to allow cell 
Buffer Components
PBS 16 mM Na2HPO4, 4 mM NaH2PO4, 150 mM NaCl
TAE 40 mM Tris-acetate, 1 mM EDTA, pH 8.0
TE 10 mM Tris, 1 mM EDTA, pH 8.0
HEK Medium
Inoue Transformation Buffer
90% DMEM + Glutamax (1x) + 4.5 g/L Glutamate - 
pyruvate; 10% FBS; 1x  Na+Pyruvate; 1x Penicillin-
Streptomycin
10.88 g MnCl2, 2.2 g CaCl2, 18.65 g KCl, 2.13 g BES 
and H2O to a total volume of 1l
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lysis. Still on ice, 200 µl of miniprep solution III (3.375 M potassium acetate and 2 M acetic acid) in 
water was added, the mixture vortexed, incubated for 5 mins on ice to allow its neutralisation and 
centrifuged (5 mins at 14,000 rpm). 30 mg RNAase A was then added and mixture was incubated at 
37C on a heat block for digestion. 300 µl Phenol:Chloroform:Isoamylalcohol (25:24:1) was then 
added, mixture vortexed for 15 seconds, centrifuged (5 mins at 14,000 rpm) and aqueous layer 
transferred to new tube in order to clean up sample. 1 ml of 100% EtOH was then added to 
precipitate DNA and mixture was then centrifuged at 4C (5 mins at 14,000 rpm) and dried. This was 
repeated with 500 µl 70% EtOH. Plasmid DNA was then resuspended in 50 µl H2O or TE buffer and 
analysed by Nanodrop spectrometry (see below for details), restriction digest and gel 
electrophoresis. Typical yields of 0.1 µg per µl.  
Maxipreparation of plasmid DNA 
Method based on Qiagen [Hilden, Germany] Plasmid Maxi protocol, using QIAGEN-tip 500.  
A single colony from a freshly streaked plate was picked to inoculate a 2 ml LB containing 200 µg.ml-1 
Ampicillin pre-culture, which is then incubated for 6 hrs at 37C with vigorous shaking (250 rpm). 
100 µl of this pre-culture was then used to inoculate 100 ml LB containing 200 µg.ml-1 Ampicillin 
culture in a 1 L Erlenmeyer flask, which was incubated for 19 hrs at 37C with vigorous shaking (250 
rpm). Culture was then centrifuged at 4C (6500 rpm in a Beckman JA-14 rotor) and cleared of 
medium. Pellet was then processed as specified in Qiagen Plasmid Maxi protocol and plasmid DNA 
was resuspended in 300 µl TE buffer (pH 8.0). Yield was determined by Nanodrop spectrometry (see 
below) and volume adjusted to achieve a DNA concentration of 1 µg.µl-1; typical yields of 300 to 600 
µg of plasmid DNA were obtained.  
Polymerase Chain Reaction 
cDNA fragments containing coding sequence of the mutations S949A and TTT865/868/869AAA were 
designed and generated by Professor Ralf Schoepfer and by Moheb Costandi.  
Strategy for the construction of N- and C-terminally eGFP-tagged Wild Type hLrrc7 fusion constructs 
was designed by Dr Agnes Thalhammer.  
cDNA fragments containing the coding sequence of eGFP were generated by Polymerase Chain 
Reaction (PCR). This was performed in 50 µl 1x KOD Polymerase buffer [Toyobo, Osaka, Japan], 
containing 1:100 dilution of pBS.EGFP-MT-CK2a [30] miniprep DNA with 0.4 µM of each primer, 0.2 
mM of each nucleotide and 1.25 Units of KOD Polymerase enzyme [Toyobo, Osaka, Japan]. The PCR 
cycle was started with a 95C, 5 min hot start step, in order to heat activate polymerase and to 
ensure melting of all DNA components, and was followed by 30 rounds of: a) melting, 95C; b) 
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annealing, at lowest predicted primer Tm, c) polymerisation, 72C. The cycle ended with a pause at 
10C. Products were separated by gel extraction, which was followed by analytical restriction digests 
prior to usage in subcloning steps.  
Estimation of DNA concentration 
Throughout, DNA concentrations and 260/280 readings were estimated using a Nanodrop 1000 
spectrophotometer [Thermo Scientific, Waltham, Massachusetts, USA]. 
Restriction enzyme digestion of DNA 
0.5 µg (analytical) to 4 µg (preparative) plasmid DNA was digested with 5 Units of restriction 
enzyme(s) in a total volume of 20 to 50 µl with appropriate buffers and conditions, as specified by 
enzyme suppliers [New England Biolabs, Ipswich, Massachusetts, USA]. Products were separated and 
purified by gel extraction prior to usage in ligation step(s).  
Agarose gel electrophoresis of DNA 
DNA was run in TAE buffer on 0.6% to 1.2% Agarose gels containing 0.5 µg.ml-1 Ethidium Bromide. 
SeaKem LE Agarose [Lonza, Basel, Switzerland] was used for analytical gels and SeaKem GTG, low-
melting Agarose [Lonza, Basel, Switzerland] was used for purification of DNA fragments. Orange G 
buffer (1 mg.ml-1, 10 mM Tris-HCl pH 7.5 and 30% Glycerol) was used as DNA loading buffer.  
-phage DNA digested with StyI or pBluescript II KS+ (Stratagene) plasmid DNA digested with MspI 
were used as DNA standard ladders.  
Gel extraction of DNA fragments 
Following separation of DNA fragments by electrophoresis on GTG Agarose gels, desired DNA 
fragments were excised and purified using the JETSORB DNA extraction kit [GENOMED GmbH, 
Löhne, Germany] following instructions available on manufacturer website http://www.genomed-
dna.com/. 
Ligation of DNA fragments 
Reaction was carried out in a total volume of 10 µl 1x Ligase buffer (supplied by manufacturer), 
containing vector and insert fragments in a 1:1 volume ratio and 1-2 Units of T4 DNA Ligase [Roche, 
Penzberg, Upper Bavaria, Germany]. Reaction mixture was then incubated overnight at 16C.  
Preparation of frozen stocks of chemically competent E. Coli cells 
Based on protocol from Hannah Morgan, Stocker lab. Modified from Inoue et al [58] 
DH5- were streaked on an LB plate and incubated for 16 to 20 hrs at 37C. A single colony was 
picked to inoculate a 25 ml SOB medium [Difco, BD – Diagnostic Systems, New Jersey, USA] starter 
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culture (prepared per label directions), which was incubated at 37C for 6 to 8 hrs with vigorous 
shaking (250 rpm). From this, 3 x 130 SOB medium cultures in 1 L Erlenmeyer flasks were inoculated 
with: 1) 5 ml starter culture; 2) 2 ml starter culture; 3) 1 ml starter culture and were incubated for 16 
to 20 hrs at 18C. Absorption readings were measured and cultures with OD600 of 0.55 to 0.6 were 
processed on ice, following sterile handling procedure.  
First, cultures were centrifuged at 4C (4,000 rpm in a Beckman JA-10 rotor), supernatant was 
removed, cells were resuspended in 40 ml Inoue transformation buffer and incubated on ice for 10 
mins. These were then centrifuged again at 4C (4,000 rpm in a Beckman JA-10 rotor), cleared of 
supernatant and resuspended in 5 ml Inoue transformation buffer. 750 µl DMSO (pure grade) was 
added to suspension while gently shaking mixture; 100 µl aliquots were made in 1.5 ml Eppendorf 
tubes, shock frozen with liquid nitrogen and stored at -70C. 
Competence was tested by transforming with pBluescriptII KS+ plasmid (Stratagene) yielding 
efficiencies on LB containing 100 µg.ml-1 Ampicillin agar plates of 2 to 3x107 colonies per µg DNA. 
Transformation of chemically competent E. Coli cells 
For each transformation, 1 (100 µl) aliquot of frozen chemically competent cells was thawed on ice. 
10 µl of DNA solution was added and mixture incubated on ice for 10 mins before 5 min incubation 
at 37C in a waterbath, after which 110 µl LB medium was added and mixed in gently. The mixture 
was then incubated for 15 mins at 37C for 15 mins and plated onto LB + 100 µg.ml-1 Ampicillin agar 
plates, which were then incubated overnight at 37C. 
PEG (polyethylene glycol) precipitation of DNA 
Used to clean up Miniprep DNA for sequencing.  
In a 1.5 ml Eppendorf tube, 8 µl of miniprep DNA (4 µg DNA) was precipated on ice in 2 µl of 4 M 
NaCl and 10 µl of 13% PEG solution for 15 mins. This was centrifuged for 15 mins at 14,000 rpm at 
4C. Supernatant was removed by careful pipetting, making sure not to disturb invisible pellet, which 
was then washed once with 50 µl 70% EtOH, air-dried and resuspended in 10 µl H2O. DNA 
concentration was estimated using a Nanodrop spectrophotometer.  
DNA sequencing 
Clean DNA was sequenced via the dideoxy method using the BigDye v3.1 terminator cycle 
sequencing kit [Applied Biosystems Inc]. A 10 µl total volume containing 1x BigDye Sequencing 
buffer, 1x Ready Reaction Premix, 3.2 pmol of primer and 400 ng of template DNA was cycled as 
follows: a) 96C, 5 mins, hot start, followed by 30 cycles of b) DNA melting, 96C, 30 seconds; c) 
annealing, 50C, 15 seconds; d) polymerisation, 60C, 4 mins, and ending with e) pause at 10C.  
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Reactions were precipitated in 24 µl 100% EtOH and 1 µl 3 M NaAc pH 4.5 on ice for 15 mins and 
centrifuged at 4C at 14,000 rpm (Biofuge 1.3, Heraeus) for 15 mins. Supernatant was carefully 
removed, pellet washed with 50 µl 70% EtOH and air dried. This was processed in-house by Stuart 
Martin in the Andrew Huxley building at UCL. Sequencing files were analysed with Sequencher v3.1 
(Gene Codes Corporation Inc.). Accurate sequences of 500 to 700 base pairs were generally 
obtained.  
HEK-TSA cell expression system 
All solutions used below are autoclaved or sterile filtered to ensure sterility. Sterile handling 
procedure is used throughout and most parts described are conducted in microbiological hazard 
containment unit. 
Thawing HEK-TSA cells 
Aliquots stored in -140C Nitrogen storage device were thawed in 37C waterbath over a couple of 
mins. Using sterile handling procedure, 1 ml HEK medium, pre-warmed to 37°C, was added to vial 
and contents transferred to a 14 ml tube, to which a further 8 ml warm HEK medium was added. 
This was then centrifuged at 800 rpm for 3 mins in a Megafuge 1.0 [Hereaus], cleared of 
supernatant, resuspended in 5 ml warm HEK medium, transferred to a 28 cm2 flask and, then, left 
overnight in a humidified incubator at 37C, 5% CO2. Medium was changed the next day, cells 
checked and flask replaced in humidified incubator. 3 days later, cells were confluent enough for 
splitting into 80 cm2 culture flasks. 
Splitting HEK cells 
Medium is removed from confluent cells in 80 cm2 culture flask and replaced with 1x PBS which is 
left to stand on the monolayer for a few seconds. 1x PBS is then replaced with 5 ml 1x Trypsin and 
trypsinisation is allowed for 1 min. 5 ml of warm HEK medium is added to stop trypsinisation and 
monolayer is rinsed with this solution a few times to resuspend cells. Suspension is transferred to a 
new 14 ml tube and centrifuged (3 mins at 2000 rpm in Megafuge 1.0, Heraeus). Supernatant is 
removed and pellet resuspended in 10 ml warm HEK medium. Cell count is estimated using 
haemocytometer and cells plated in warm HEK medium in the following amounts:  
-5 to 7x105 cells for 80 cm2 culture flasks or 9 cm diameter culture dish with total volume of 10 ml, -
7.5x104 cells for Laminin and poly-D-ornithine coated 13 mm diameter coverslips in 24-well plates 
with total volume of 500 µl.  
These are left in a humidified incubator (37C, 5% CO2). Cells are confluent for next splitting 3 days 
later.  
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Transfection of HEK-TSA cells using Lipofectamine 2000 reagent 
50 µl of Lipofectamine 2000 solution (2 µl of Lipofectamine 2000 reagent in 48 µl OptiMEM) was 
added to 50 µl of 1 µg DNA in OptiMEM and left to form complexes for 30 mins. Medium was 
removed from 60% confluent cells on coverslips, the 100 µl of Lipofectamine 2000 + DNA solution 
was added and incubated in humidified incubator (37C, 5% CO2) for 20 mins. This was then replaced 
with warm HEK medium; cells were then replaced in incubator overnight and checked for expression 
the following day.  
Confocal microscopy 
The localisation of recombinant fusion protein in HEK-TSA cells was examined by confocal 
microscopy. Following transfection and appropriate expression time (1 to 2 days), cells were fixed in 
4% PFA, 4% sucrose and 1x PBS solution and coverslips mounted onto SuperFrost microscope slides 
using Gel Mount Aqueous Mounting Medium.  
A Radiance 2100 system [BioRad, Hercules, California, USA] was used to take stack images with an 
oil-immersion 100x oil objective + 2.8x optical zoom with 0.2 µm step size, corresponding to a lateral 
resolution of 212.63 nm and an axial resolution of 520 nm (computed using resolution calculator on 
the MRC Cell Biology Unit’s Light Microscopy Facility website). A 488 nm Argon laser was used for 
excitation of eGFP-tag and a Green HeNe laser at 543nm excitation wavelength for excitation of co-
expressed mRFP. The pinhole size was set to 1.4 Airy disc units.  
Analysis 
Analysis was carried out using ImageJ, MS Excel and IgorPro. Raw stack images were Z-projected 
(Images => Stacks => Z-Project: maximum intensity) and colour channels were merged (Image => 
Colour => Merge Channels) prior to analysis to improve file handling.  
Fluorescence profile analysis 
This was done on eGFP signal of cells by applying the plot profile function (Analyze => Plot profile) on 
straight line selections drawn across each cell being analysed. The data was then exported into MS 
Excel and analysed to determine the occurrence of type I, type II or other subcellular behaviour.   
Particle distribution analysis 
Files were blind labelled, kindly done by Yogesh Malam, in order to reduce bias in this analysis. 
eGFP-channel of images was manually thresholded to produce binary representations of Densin-180 
subcellular distribution (Images => Adjust => Threshold) on which particle analysis was carried out 
(Analyze => Analyze Particles: particle size = 0 to infinity; circularity = 0 to 1). This is shown in the 
figure below.  
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Raw particle area data was exported to MS Excel, blind labels were decoded and the data were 
concatenated according to Densin-180 variant imaged. This data was then imported into IgorPro and 
histograms were computed (Analysis => Histogram); a minimum area cut-off was worked out to be 
0.04521 µm2 (= microscope lateral resolution2) and bin sizes were set to twice this value in order to 
prevent subsampling, in accordance to Nyquist’s Theorem. Cumulative frequency distribution and 
Kolmogorov-Smirnoff tests were computed In MS Excel; all graphs were generated using IgorPro.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following page. Workflow: 2D particle distribution analysis. Image channels are split, the eGFP 
channel is thresholded and particle analysis is run on this 8-bit data yielding particle data.  
45 
 
46 
Results 
Cloning overview 
For cloning purposes, hLrrc7 construct was shuffled into pBluescriptII KS+ vector (Stratagene).  
Tagging the N-terminus 
This was done using an Overlap Extension Joining PCR approach, joining 2 PCR products.  
PCR1 (schema 1-1), designed to amplify the first coding sequence of Densin-180’s first 33 amino 
acids from the vector backbone, also adds a 17 base pair overhang complimentary to the first 24 
base pairs of the eGFP coding sequence.  
 
Schema 1-1. PCR1 amplifies the Densin-180 N-terminus coding sequence and the KS+ Multiple 
Cloning Site (MCS). Template: KS+-hLrrc7-unrepaired. Sense primer: KSpIMCS-Seq1-s. Antisense 
primer: EGFP-hLrrc7-PCR1-a. Red: Densin code. Black: vector code. Green: MCS.  
 
PCR2 (schema 1-2) was designed to amplify the eGFP coding sequence (excluding stop codon) from 
pBS.EGFP.MT.CK2a [30], adding a 19 base pair overhang complimentary to the end 19 base pairs of 
PCR1 product fragment, preceding the eGFP coding sequence, and introducing a BglII site following 
the eGFP coding sequence.  
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Schema 1-2. PCR2 amplifies the eGFP coding region. Template: pBS.EGFP.MT.CK2a. Sense primer: 
EGFP-hLrrc7-PCR2-s. Antisense primer: EGFP-PCR2-a (designed by Cezar E. Tigaret). Green: eGFP 
coding. Black: vector coding. 
 
Essentially, the primers EGFP-hLrrc7-PCR1-s and EGFP-hLrrc7-PCR2-s are almost fully complimentary: 
the product fragments obtained from PCR1 and PCR2 have 36 bp complementary overhangs 
(schema 1-3), on which the Overlap Extension Joining PCR relied on.   
 
Schema 1-3. PCR3: 1st desired reaction in Overlap Extension Joining PCR in which the products of 
PCR1 (top) and PCR2 (bottom) act both as primers and templates for the reaction. Red: Densin code. 
Green: eGFP code.  
 
The Overlap Extension Joining PCR (PCR3) used: the products of PCR1 and PCR2 as both templates 
and primers; the outer primers used in PCR1 and PCR2, also as primers, this time priming 
amplification of the first product in the reaction (schema 1-4).  
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Schema 1-4. PCR3: the product of reaction shown in schema 1-3, the desired end product, is amplified 
by outer primers from PCR1 and PCR2. Red: Densin code. Green: eGFP coding. 
 
The product derived from PCR3 was shuffled into pRSET6a-Ca-His vector using SacI and BglII 
restriction sites (schema 1-5).  
 
Schema 1-5. pRSET6a-Ca-His used here as an intermediate cloning vector.  
 
The final PCR, PCR4, amplified Densin-180 sequence containing XhoI restriction site, necessary for 
the ultimate replacement of untagged N-terminus with eGFP-tagged N-terminus, downstream of 
Densin-180 sequence coded in PCR3 derived fragment, while adding a BamHI site for shuffling into 
intermediate construct (pRSET6a-Ca-His-PCR3) immediately adjacent to PCR3 derived sequence 
(BamHI and BglII have compatible ends). 
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Schema 1-6 – PCR4: Amplification of Densin-180 code downstream from where it was left off in PCR1. 
Template KS+-hLrrc7-unrepaired. Sense primer: hLrrc7-PCR1-s. Antisense primer: hLrrc7-Seq11-a. 
Red: Densin coding.  
 
The PCR4 derived product was shuffled into intermediate construct using BamHI/BglII and NcoI 
restriction sites (schema 1-7).  
 
Schema 1-7.  Insertion of PCR4 product via BglII and NcoI into intermediate vector where PCR3 
product has been inserted.  
 
The thereby joined PCR3xPCR4 derived stretch containing the eGFP-tagged Densin-180 N-terminus 
was shuffled into Densin-180 construct, replacing untagged N-terminus, using NotI and XhoI 
restriction sites (schema 1-8).  
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Schema 1-8. Shuffling eGFP tagged Densin-180 N-terminus coding sequence from intermediate 
cloning vector and into untagged Densin-180 construct via NotI and XhoI restriction sites, replacing 
untagged N-terminus code.  
Tagging the C-terminus  
This was done using Overlap Extension Joining PCR, the same principle used to tag the N-terminus 
(schema 2-1): PCR1’ was used to amplify the Densin-180 C-terminus coding region, replacing the 
stop codon with a 24 base pair stretch equating to the N-terminal eGFP code sequence; PCR2’ was 
used to amplify the eGFP coding sequence, adding a 23 base pair stretch equating to the C-terminal 
Densin-180 code and introducing the KpnI restriction ultimately necessary for the shuffling of the 
eGFP-tagged Densin-180 C-terminus code into full construct.  
 
Schema 2-1 – PCR1’: amplification of Densin-180 C-terminus, excluding stop codon. Template: KS+-
hLrrc7-unrepaired. Sense primer: hLrrc7-Seq6-s. Antisense primer: EGFP-hLrrc7-PCR4-a. Red: Densin 
coding. 
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Schema 2-2 – PCR2’: amplification of eGFP coding sequence, including stop codon and addition of 
KpnI cloning site using primer overhang on EGFP-PCR8-a. Template: pBS.EGFP.MT.CK2a. Sense 
primer: EGFP-hLrrc7-PCR3-s. Antisense primer: EGFP-PCR8-a.  
 
Schema 2-3 – PCR3’: Overlap Extension Joining PCR. In the 1st reaction products from PCR1’ and 
PCR2’ act as both primers and templates. The product of this reaction, the desired end product, is 
amplified by outer primers. Templates: PCR1’ and PCR2’ products. Sense primer: hLrrc7-Seq6-s. 
Antisense primer: EGFP-PCR8-a. Red: Densin coding. Green: eGFP coding.  
 
 
 
Schema 2-4 – PCR3’: Overlap Extension Joining PCR end product. Red: Densin coding. Green: eGFP 
coding. 
 
The product of PCR3’ was shuffled into KS+-hLrrc7 using KpnI and SmaI sites, replacing the untagged 
C-terminus coding stretch.  
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Schema 2-5. KS+-hLrrc7-unrepaired. KpnI and SmaI restriction sites used to replace untagged C-
terminus with eGFP tagged C-terminus coding sequence.  
Repairing the clone (re-introduction of missing 4 exons) and insertion of mutations 
As mentioned at the beginning of this section, the clone, acquired from Open Biosystems, was found 
to be missing 4 exons. A nested PCR (the resulting fragment is labelled “PCR 2 in schema 3-1) was 
carried out on rat cDNA (kindly provided by Dr Martin Stocker) by Dr Agnes Thalhammer to generate 
a DNA fragment of sequence corresponding to the missing segment. To consider the inter-species 
difference between human and rat a sequence alignment done using Readseq 
(http://www.ebi.ac.uk/cgi-bin/readseq.cgi) found that 97.7% of sequence identity is shared between 
the two sequences: the differences can be deemed negligible.  
This repair fragment and the mutation fragments generated by Moheb Costandi, by PCR site-
directed mutagenesis and gene splicing by Overlap Extension Joining PCR, were introduced into 
eGFP-hLrrc7 fusion constructs, as illustrated in schema 3-1 and the following four constructs were 
obtained as confirmed by sequencing: KS+-N-eGFP-hLrrc7-WT, KS+-N-eGFP-hLrrc7-
TTT865/868/869AAA, KS+-hLrrc7-eGFP-C-WT and KS+-hLrrc7-eGFP-C-TTT865/868/869AAA. 
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Schema 3-1 Cloning of repair fragment and mutation fragments into N-eGFP-hLrrc7 and hLrrc7-eGFP-
C fusion constructs. 
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Shuffling constructs into pRK7, an expression vector, for expression in mammalian cell expression 
systems 
First, the vector had to be modified, to include the required cloning sites in the correct order, for the 
shuffling and correct expression of the expression constructs in mammalian cells. A NotI restriction 
site, contained within specifically ordered oligonucleotides, was inserted via HindIII and SalI 
restriction sites (schema 4-1).  
 
Schema 4-1. pRK7a, with HindIII and SalI restriction sites (in bold), and oligonucleotides, with HindIII 
and SalI overhangs, containing NotI restriction site (shown in bold).  
 
All Densin-180 constructs were shuffled into the modified vector, named pRK7a, via NotI and KpnI 
restriction sites (schema 4-2). 
 
Schema 4-2. N-eGFP-hLrrc7-WT-FULL in KS+ cloning vector and pRK7a. NotI and KpnI sites shown in 
bold. 
This resulted in the following expression constructs: pRK7a-N-eGFP-hLrrc7-WT, pRK7a-N-eGFP-
hLrrc7-TTT865/868/869AAA, pRK7a-hLrrc7-C-WT and pRK7a-hLrrc7-eGFP-C-TTT865/868/869AAA.  
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Generating PDZ truncation constructs 
3 N-terminally tagged PDZ truncation constructs were generated with different C-terminal amino 
acid sequences (shown below). The strategy for their construction involved generating the coding 
sequences for these endings by PCR and then inserting these via BamHI and AccIII restriction sites 
(schema 5-1), thereby replacing the original PDZ-domain containing C-terminus coding sequence in 
the starting construct, pRK7a-N-eGFP-hLrrc7-WT.  
 
Schema 5-1. pRK7a-N-eGFP-hLrrc7-WT-FULL with BamHI and AccIII restriction sites shown in bold. 
 
Although the same template (pRK7a-N-eGFP-hLrrc7-WT) and sense primer (hLrrc7-Seq6-s) were 
used for all 3 PCRs, each reaction relied on their own, specific, antisense primers to generate the 
desired, individual endings, by virtue of the primer overhangs (as shown below).  
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Legend: 
Blue – densin-180 coding 
Yellow – PDZ-domain coding 
Red – BamHI cut site 
  
Construct A – pRK7a-N-eGFP-hLrrc7-WT-PDZ-DGYPQRELTVstop 
hLrrc7-PCR11-a 
1-ATGggatccTTAGACAGTAAGCTCACGTTGTGGATATCCATCCATACTCC-50 
In reverse complementary: 
   GGAGTATGGATGGATATCCACAACGTGAGCTTACTGTCTAAggatccCAT 
           S     M     D     G    Y     P     Q     R     E      L     T     V     * 
 
 
Construct B – pRK7a-N-eGFP-hLrrc7-WT-PDZ-DGYPstop 
hLrrc7-PCR12-a 
1-ATGATGggatccTTATGGATATCCATCCATACTCCT-36 
In reverse complementary: 
   AGGAGTATGGATGGATATCCATAAggatccCATCAT 
      R     S     M     D     G    Y     P     * 
 
 
Construct C – pRK7a-N-eGFP-hLrrc7-WT-PDZ-QREstop 
hLrrc7-PCR13-a 
1-ATGATGggatccTTACTCACGTTGAATAACTAGGTC-36 
In reverse complementary: 
   GACCTAGTTATTCAACGTGAGTAAggatccCATCAT 
      D     L     V     I      Q     R    E      * 
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hLrrc7 phospho-rich region deletion constructs 
The sequence coding for Densin-180’s phosphorylation rich region, removing the region coding for 
amino acids 702 to 1422 without the introduction of frameshift, from pRK7a-N-eGFP-hLrrc7-WT-
FULL and pRK7a-hLrrc7-eGFP-C-WT-FULL expression constructs, using XmaI restriction sites (schema 
6.1). 
 
Schema 6-1. pRK7a-N-eGFP-hLrrc7-WT-FULL and pRK7a-hLrrc7-eGFP-C-WT-FULL expression 
constructs, with XmaI restriction sites labelled, before and after removal of phosphorylation rich 
region coding sequence.  
 
58 
Expression of recombinant Densin-180 constructs in HEK cells 
N-WT vs C-WT 
Expressed protein displayed characteristic subcellular localisation depending on whether the eGFP 
tag was introduced N-terminally or C-terminally in the protein (figure 2-1). N-terminally eGFP-tagged 
wild type Densin-180, pRK7a-N-eGFP-hLrrc7-WT, displayed punctate distribution while the C-
terminally eGFP-tagged wild type Densin-180, pRK7a- hLrrc7-WT-eGFP-C-WT lacked puncta and 
displayed a more diffuse distribution. When observed by eye, the TTT865/868/869 variants of these 
constructs did not display any differences in subcellular localisation when compared to their wild 
type counterparts, seemingly following the same patterns. 
Fluorescence profile analyses of single cell cross sections (figure 2-2) provide semi-quantitative 
support to these observations, showing two clear behaviours:  
 Type 1: shared by N-terminally eGFP-tagged constructs pRK7a-N-eGFP-hLrrc7-WT and 
pRK7a-N-eGFP-hLrrc7-TTT865/868/869AAA. Distinctive peaks representing punctate 
formations in cell cytoplasm and large dip in signal in large central area, representing the 
nucleus.  
 Type 2: shared by C-terminally eGFP-tagged constructs pRK7a-hLrrc7-eGFP-C-WT and pRK7a-
hLrrc7-eGFP-TTT865/868/869AAA. Signal is level across the cell and neither distinctive peaks 
nor dip in signal where nucleus is are observed.  
The breakdown of the distribution of cells fitting into these two types of behaviour, shown in 
table 2-1, provides further semi-quantitative evidence for this trend. Notice the shift from type 1 
to type 2 behaviour upon the introduction of the triple phosphonull mutation in the N-terminally 
eGFP-tagged Densin-180 variants.  
Type 1 Type 2 Other
N-WT 78% (14) 0% (0) 22% (4)
N-TTT 50% (11) 23% (5) 27% (6)
C-WT 0% (0) 63% (12) 37% (7)
C-TTT 6% (1) 69% (11) 25% (4)  
Table 2-1. Distribution of cells into type 1, type 2 and other subcellular behaviours as assessed by 
fluorescence profile analysis. Data shown in percentages and number of cells (in brackets).  
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Figure 2-1. Subcellular localisation of eGFP-tagged Densin-180 fusion constructs coexpressed with 
mRFP in HEK cells (flattened stack images). Top left: pRK7a-N-eGFP-hLrrc7-WT. Top right: pRK7a- 
hLrrc7-eGFP-C-WT. Bottom left: pRK7a-N-eGFP-hLrrc7-TTT865/868/869AAA. Bottom right: pRK7a-
hLrrc7-eGFP-C-TTT865/868/869AAA. Flattened stack images. Scale: 44 µm x 44 µm.  
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Figure 2-2a. Fluorescence profile analysis of eGFP signal in cross sections of HEK cells expressing 
pRK7a-N-eGFP-hLrrc7-WT, N-WT (top left), pRK7a-N-eGFP-hLrrc7-TTT865/868/869AAA, N-TTT 
(bottom left), pRK7a-hLrrc7-eGFP-C-WT, C-WT (top right), and pRK7a-hLrr7-eGFP-C-
TTT865/868/869AAA (bottom right). 
 
Figure 2-2b. Example cells used for fluorescence profile analysis, with cross section drawn across 
cells. Left: cell expressing N-terminally eGFP-tagged wild type Densin-180, showing green channel 
only. Right: cells expressing C-terminally eGFP-tagged TTT865/868/869AAA Densin-180, showing red 
(cell filler) and green channels. Scale = 44 µm x 44 µm. 
61 
2D particle analysis provide further support to these observations (figure 2-3), with the histogram 
(top) showing the N-terminally eGFP-tagged Densin-180 wild type variant expressing approximately 
10 times more particles than its C-terminally eGFP-tagged counterpart. Interestingly, HEK cells 
expressing N-terminally eGFP-tagged WT Densin-180 showed approximately 40% more particles 
than cells expressing the N-terminally eGFP-tagged TTT865/868/869AAA variant, however, there 
was no major difference between the amount of particles seen in HEK cells expressing C-terminally 
eGFP-tagged Densin-180 wild type and C-terminally eGFP-tagged Densin-180 TTT865/868/869AAA. 
The distribution of particles below optical resolution, omitted from the top histogram, is shown in 
the histogram on the bottom left of figure 2-3. This is interesting, in that it shows that the C-
terminally eGFP-tagged variant containing the triple phosphonull mutation forms fewer particles 
than its wild type counterpart.  
Cumulative frequency distributions reflect the two types of behaviour outlined above, with N-
terminally eGFP-tagged constructs showing prominent formation of smaller particles when 
compared to the C-terminally tagged constructs. Interestingly, both N-terminally and C-terminally 
eGFP-tagged TTT865/868/869AAA variants show a common sub-behaviour: both closely followed 
their Wild Type counterparts’ behaviours, but both exhibited a small inhibition in the formation of 
small particles, visible by a small rightward shift in the distribution curve.  
Constructs D value Critical value
N-WT vs C-WT 0.21255 0.044862
N-WT vs N-TTT 0.017243 0.044862
N-WT vs C-TTT 0.160767 0.044862
C-WT vs N-TTT 0.20717 0.044862
C-WT vs C-TTT 0.05469 0.044862  
Table 2-2. Kolmogorov-Smirnoff test results.  
Kolmogorov-Smirnoff tests (table 2-2) support these two behaviours distinct between N-terminally 
and C-terminally eGFP-tagged Densin-180 variants, with D values larger than critical values by a 
sizeable margin. However, the test shows weaker support for the effect of the triple-phosphonull 
mutation, supporting difference between C-terminally eGFP-tagged wild type and 
TTT865/868/869AAA with a D value close to the critical value and identical distributions of N-
terminally eGFP-tagged wild type and TTT865/868/869AAA variants. 
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Figure 2-3. Particle distribution of N- and C-terminally eGFP-tagged Densin-180 fusion constructs. N-
WT, pRK7a-N-eGFP-hLrrc7-WT, (red), n cells = 18. C-WT, pRK7a-hLrrc7-eGFP-C-WT (cyan), n cells = 
19. N-TTT, pRK7a-N-eGFP-hLrrc7-TTT865/868/869AAA (brown), n cells = 22. C-TTT, pRK7a-hLrrc7-
eGFP-C-TTT865/868/869AAA (blue), n cells = 16. Histogram (top): bin start = 0.04521 µm2; bin size = 
0.09 µm2. Histogram (bottom left): bin start = 0 µm2; bin size = 0.04521 µm2. Cumulative frequency 
plot (bottom right) and with logarithmic x axis (inset). N-terminally and C-terminally eGFP-tagged 
variants show distinct distributions. 
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The results presented below are from experiments kindly carried out by Dr Agnes Thalhammer and 
Shi Yi Wang.  
PDZ deletion constructs 
Visually, each of the PDZ truncation constructs presented distinct subcellular localisation in HEK cells 
(figure 2-4):  
- Expressed pRK7a-N-eGFP-hLrrc7-PDZ-A, in which the PDZ domain is truncated with the 
exception of the last 5 amino acids, forms cytosolic puncta in smaller quantities than in N-
terminally tagged wild type construct, some in proximity to cell membrane.  
- Expressed pRK7a-N-eGFP-hLrrc7-PDZ-B, in which the PDZ domain remains intact and only 
the protein’s terminal three amino acids are truncated, appears diffusely distributed across 
the cell with some aggregate formations.  
- Expressed pRK7a-N-eGFP-hLrrc7-PDZ-C, in which the entire PDZ domain and C-terminal 
amino acids are truncated, forms puncta again in smaller amounts than expressing N-WT, 
and diffusely, showing some preference for membrane proximal localisation.  
Based on visual observations, all three constructs presents phenotypes individual from the N-
terminally eGFP-tagged wild type construct.  
Particle analysis (figure 2-5) supports this, showing that PDZ-A, -B, and –C produce approximately 10 
times fewer particles than the N-terminally eGFP-tagged wild type construct. The relationship 
between the PDZ deletion constructs and the wild type is similar to that between C-WT and N-WT 
constructs. This data should only be considered in a semi-quantitative respect since n number for 
each PDZ deletion construct = 4 cells from 2 transfection experiments, and, therefore, cannot be 
statistically substantiated.  The weakness of the data can be seen in the jagged appearance of the 
cumulative frequency distribution curves for PDZ-A to –C.  
eGFP fluorescence profile analysis (figure 2-6 and table 2-3) suggest that the PDZ / C-terminal 
variants have a preference for type 2 behaviour, resembling behaviour exhibited by C-terminally 
eGFP-tagged Densin-180 variants, but that these can still express type 1 behaviours, resembling N-
terminally eGFP-tagged Densin-180 variants (e.g. PDZ-C). It should be noted that this data only 
provides semi-quantitative indications.  
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Type 1 Type 2 Other
PDZ A 25% (1) 50% (2) 25% (1)
PDZ B 0% (0) 100% (4) 0% (0)
PDZ C 25% (0) 75% (0) 0% (0)  
Table 2-3. Distribution of cells into type 1, type 2 and other subcellular behaviours as assessed by 
fluorescence profile analysis. Data shown in percentages and number of cells (in brackets).  
 
 
 
Figure 2-6. Fluorescence profile analysis of eGFP signals in cross sections of HEK cells expressing: 
pRK7a-N-eGFP-hLrrc7-PDZ-A, PDZ-A (orange); pRK7a-N-eGFP-hLrrc7-PDZ-B, PDZ-B (blue); pRK7a-N-
eGFP-hLrrc7-PDZ-C, PDZ-C (cyan); pRK7a-N-eGFP-hLrrc7-WT coexpressed with mRFP-CaMKII-α, N-WT 
+ CaMKII-alpha (red); and pRK7a-hLrrc7-eGFP-C-WT coexpressed with mRFP-CaMKII-α, C-WT + 
CaMKII-alpha (black).   
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Figure 2-5. Particle distribution of N-terminally eGFP-tagged PDZ deletion constructs: pRK7a-N-eGFP-
hLrrc7-PDZ-A, PDZ-A (orange); pRK7a-N-eGFP-hLrrc7-PDZ-B, PDZ-B (blue); pRK7a-N-eGFP-hLrrc7-
PDZ-C, PDZ-C (cyan), and pRK7a-N-eGFP-hLrrc7-WT, N-WT (red). For all except N-WT, n = 4 cells from 
2 transfection experiments; for N-WT, n = 18 cells from 2 transfection experiments. Histogram (top): 
bin start = 0.04521 µm2; bin size = 0.09 µm2. Histogram (bottom left): bin start = 0 µm2; bin size = 
0.04521 µm2. Cumulative frequency plot (bottom right).  
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Coexpression of CaMKII-α leads to retargeting of Densin-180 
mRFP-tagged CaMKII-α (pBS.RFP-MT-CK2a [30]) was coexpressed with N- and C-terminally tagged 
wild type Densin-180 in HEK cells (figure 2-7). The orange colour seen in cells when CaMKII-α is 
coexpressed with both N- and C-terminally tagged variants of Densin-180 is most probably due to 
some degree of colocalisation of CaMKII-α with Densin-180, leading to a mixing of the green 
representing the eGFP signal with the red representing the mRFP signal.  
The apparent decrease in the size of N-terminally tagged wild type Densin-180 puncta and the 
apparent shift in localisation of C-terminally tagged Densin-180 towards the plasma membrane, 
when these constructs are coexpressed with CaMKII-α may be artifactual, and more experiments 
would have to be carried out, followed by quantitative analysis in order to substantiate these 
observations.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7 (following page). Subcellular localisation of N- and C-terminally eGFP-tagged Densin-180 
constructs in HEK 293 cells. Top left: N-eGFP-hLrrc7-WT, coexpressed with mRFP cell filler; scale – 60 
µm x 60 µm x 2.62 µm. Top right: N-eGFP-hLrrc7-WT, coexpressed with mRFP-CaMKII-α; scale – 60 
µm x 60 µm x 2.46 µm. Bottom left: hLrrc7-eGFP-C-WT coexpressed with mRFP cell filler; scale – 
82.12 µm x 82.12 µm x 4.25 µm. Bottom right: hLrrc7-eGFP-C-WT coexpressed with mRFP-CaMKII-α; 
scale – 82.12 µm x 82.12 µm x 3.668 µm. 
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Discussion 
The HEK 293 cell expression system 
All results presented in this thesis are derived from HEK 293 cell expression studies and, as such, do 
not reflect Densin-180’s in vivo behaviour as well as data from hippocampal primary neuron cultures 
would.  
An immortalised cell line, HEK 293 cells are a robust, easy to maintain and very reliable expression 
system. Setting up a culture is as easy as thawing a vial of cells and plating them. These cells are easy 
to handle and convenient for transfection studies. What’s more, no animals are required when using 
the HEK 293 cell expression system. Hippocampal primary neuron cultures, on other hand, are 
extremely fragile and high maintenance, requiring delicate handling. Setting up a culture requires 
tricky dissection of embryonic mice from a pregnant specimen: a tricky procedure requiring a 
practised hand. Even in experienced hands, the likelihood of failure of primary hippocampal neuron 
cultures far exceeds that of HEK 293 cell cultures.  
However, the results derived from HEK 293 cell expression studies are of a very different character 
to those from hippocampal primary neuron cultures, since HEK 293 cells do not express the 
complement of synaptic proteins specific to neurons. Out of the protein interaction partners of 
Densin-180 mentioned in the introduction section, only mRNAs from those associated with the 
cytoskeleton are found: α-actinin, δ-catenin and N-cadherin [59] [60]. This leaves a large set of 
absent Densin-180 interactors: NR2B, Cav1.3, MAGUIN-1, PSD-95, and shank are proteins, which 
have been found to have a role in determining the targeting and subcellular localisation of Densin-
180, that are simply not present in HEK cells. Densin-180’s subcellular behaviour in HEK cells should 
therefore be expected to substantially differ from its behaviour in vivo or in hippocampal primary 
neuronal cultures.  
However, the surprising presence of neuronal cytoskeletal proteins, as well as other neuronal 
proteins, considering that HEK 293 cells are derived from kidney epithelial cells, means that the 
environment presented by HEK cells to Densin-180 is not so far removed from its neuronal 
environment as would have been expected [59] [60], presenting the HEK 293 cell line as the ideal 
starting point for expression studies of neuronal proteins like Densin-180. In fact, by removing many 
of Densin-180’s interaction partners, HEK cells provide an excellent platform in which to study 
specific protein interactions and structure-function relationships in isolation from the many 
interactions Densin-180 takes part in when in neurons.  
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Image analysis methods 
A special note should be made highlighting the difficulty in analysing image data. In contrast to data 
which may be obtained from electrophysiological measurements, which are direct and quantitative, 
data obtained from measurement using a confocal microscope, with more dimensions, is qualitative. 
This, together with the biological nature of cells, presents the task of extracting some statistical 
meaningfulness from this type of data as a challenge.  
One of them main drawbacks of the analysis presented here is its two dimensional nature. Rather 
than carrying out fluorescence profile and particle distribution analyses on slices taken from stack 
images, which may misrepresent cells, or, on 3-dimensional models produced from these (possible 
using Volocity), which uses up a lot of computer power, these were carried out using Z-projections, 
presenting the trouble that particles neighbouring each other on the X and Y planes yet distanced 
from one another on the Z plane may appear to be part of the same particle, adding an element of 
error to our analyses.  
Another element of vagueness can be seen in the fluorescence profile analysis, which was based on 
analysis of a single, arbitrarily drawn cross section of each cell: the weakness is clear, in that this 
cross section may misrepresent cells, but this method provides good means of evaluating 
populations of cells in the manner described above.  
The thresholding method used in the particle analysis present another area of error: due to variation 
in the amount and intensity of eGFP signal between cells, and between particles, no automated 
thresholding algorithm available was able to threshold signal in a manner representative of visible 
signal. Because of this, thresholding was carried out manually, with the criteria that the thresholded 
image must be representative of number, shape and size of particles visible in the unthresholded 
image. This presented a number of weaknesses in the data because: each cell has a different 
threshold; particles may disappear, diminish in size, or disintegrate when threshold is increased; 
particles may appear, increase in size and fuse when threshold is decreased.  
Developing a method of printing specified areas with specified amounts of eGFP, a method of 
calibrating measured signal against amount of protein would offer a large leap in image analysis of 
expressed proteins.  
Subcellular behaviours observed via fluorescence profile analysis 
The subcellular behaviours of Densin-180 variants observed via fluorescence profile analysis 
reflected visual observations and particle distribution analysis, all suggesting the occurrence of two 
types of subcellular behaviour, with different variants showing preferences for one or the other.  
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Fluorescence profile analysis gives a good, semi-quantitative breakdown of the behaviours. As 
shown in table 2-1, N-terminally eGFP-tagged variants show a clear preference for type I behaviour, 
while C-terminally eGFP-tagged variants favour type II behaviour, reflecting what is shown in the 
particle analysis.  
Interestingly, a sizeable proportion of cells expressing the N-terminally eGFP-tagged 
TTT865/868/869AAA variant show a small shift from type I behaviour to type II behaviour; a shift, 
also reflected, somewhat, in the particle distribution.  
All variants displayed a sizeable proportion of cells (20% to 40%) expressing “other” behaviour. This 
is mainly due to aggregate formations and particles which appear fused together through Z-
projection of raw stack images. High eGFP signal intensities were also notable within the centre of 
dividing cells expressing N-terminally eGFP-tagged variants: this is likely due to Densin-180’s 
association with cytoskeletal elements of HEK293 cells. Generally, however, most cells falling into 
the “others” category shared many similarities with the type of behaviour associated with the 
Densin-180 variant expressed within those cells.  
Densin-180 aggregation 
Protein aggregation at specialised pre- and post-synaptic structures occurs during synaptic 
development, and like Densin-180, many of its interactors also form puncta: CaMKII-α (previous 
observations), MAGUIN-1 [49], PSD-95 [21], Shank [51] and Cav1.4 [61] are a few examples. Densin-
180, has also, itself, previously been observed to form puncta [45][48]. 
Interestingly, the observations presented here match previous observations: the subcellular 
localisation of the N-terminally eGFP-tagged Densin-180 construct, pRK7a-N-eGFP-hLrrc7-WT, 
matches that presented by Strack et al, who expressed the C-terminal part of Densin-180 to which 
they had added a 10 amino acid membrane targeting sequence from Lck tyrosine kinase, containing 
myristoylation and dual palmitoylation sites [14]. The Lck tyrosine kinase is found in caveolae, the 
size, shape and subcellular distribution of which is similar to that of the punctate formations 
observed here.  
Caveolae, Latin for ‘little caves’, are a type of specialised lipid rafts forming small invaginations of the 
plasma membrane of 50 to 100 nm diameter, with functions in vesicular transport, cholesterol 
homeostasis, signal transduction and tumour suppression. Their main constituent proteins, caveolin 
1-3, are known to interact with G-protein subunits and receptors, tyrosine kinases, small GTPases, 
MAP Kinases, β-adrenergic receptors, protein kinase C isoforms, Src family kinases, and have 
regulatory effects on a number of these proteins and thus on their associated signal transduction 
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pathways [63]. It is possible that in HEK cells, protein-protein interactions with proteins of caveolar 
complexes underlie the punctate localisation of Densin-180 observed.  
However, it is worthwhile considering the behaviour of other PSD proteins in HEK cells. CaMKII-α 
was found to form puncta similar to those seen when they are expressing N-terminally eGFP-tagged 
wild type Densin-180 (previous observations). CaMKII-α subunits are known to self-associate, 
forming dodecameric holoenzymes which themselves associate, which gives a rational mechanism 
underlying these aggregations. Drawing parallels with CaMKII-α, it may be possible that Densin-180 
forms puncta, also, through some mechanism of self-association. MAGUIN-1 is another example of a 
PSD protein that forms puncta through self-association: in this case dimerization or multimerisation 
occurs through the proteins C-terminal Leucine-rich region [49]. 
PSD-95 clustering, however, has a number of elements which may be of similarity to Densin-180 
clustering: clustering of this protein at the PSD requires N-terminal palmitoylation, is dependent on 
its first two PDZ domains and on its terminal 12 amino acid residues [62]. It may well be the case 
that in Densin-180, N-terminal palmitoylation and PDZ domain interactions, involving terminal 
amino acids, may constitute a mechanism protein clustering at the PSD.  
The data presented in this thesis show that N-terminally eGFP-tagged Densin-180 constructs form 
cytosolic punctate formations when expressed in HEK cells, and that C-terminally eGFP-tagged 
Densin-180 constructs show strongly inhibited punctate formation. Further, preliminary data 
presented in this thesis show that tampering with Densin-180’s PDZ domain and/or terminal amino 
acids also inhibit the formation of puncta. It is quite possible that Densin-180 dimerises or 
multimerises through interactions between its PDZ domain and its own terminal amino acid 
residues.  
Densin-180 membrane association 
Concerning membrane association of Densin-180, from observation of expressed constructs in HEK 
cells by eye, it is only possible to speculate that C-terminally eGFP-tagged constructs have a 
tendency towards membrane association over the N-terminally eGFP-tagged variants; this could be 
substantiated by membrane staining experiments, for example using a stain such as Cell Mask 
Orange [Invitrogen, Carlsbad, CA, USA], and by Western blot analysis of membrane associated 
proteins of cells expressing the various Densin-180 constructs presented here, to measure the 
colocalisation and membrane association of expressed Densin-180 proteins with cell membrane.  
Possible involvement of N-terminal Cys14/16 and LRR region in membrane association 
Although the possible role of Densin-180’s Cys14/15 residues and of its LRR region was highlighted in 
the introduction section, the data presented here does not clarify this.  
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Membrane staining experiments and Western blot analysis of membrane associated proteins would 
help ascertain the role of Densin-180’s N-terminal region: since palmitoylation is an enzyme 
dependent process, it could be expected that the process is inhibited in the N-terminally eGFP-
tagged Densin-180 constructs, and C-terminally eGFP-tagged constructs, in which palmitoylation 
may not be inhibited in the same fashion, could be found to exhibit more membrane association.  
The generation of new constructs, featuring mutations of Cys14/16 residues to Serine residues 
and/or featuring LRR region truncations, combined with expression studies using membrane staining 
and Western blot analysis of membrane bound protein fraction would offer some definitive gauge of 
the individual involvement of these Densin-180 features, if any, in its membrane association 
property.  
Protein expression levels 
The potentially varying expression levels of different constructs present a large source of variation in 
the results presented in this thesis. Expression levels may vary due to:  
 The point in the cell cycle at which the imaged cell is in, which may affect protein expression 
levels and subcellular localisation. 
 Variation in transfection efficiency depending on construct. 
 Variation in expression of transfected construct, as well as post-translational modifications.  
Variation in protein expression levels could cause variation in the size of punctate formations within 
a cell, such that a reduction in expression levels of transfected construct may cause a downward 
shift in the size and number of punctate formations and vice versa. This could mean that the type 1 
and type 2 behaviours outlined above may not be due to variation in structure, affecting the 
function, of Densin-180, but simply to variations in protein expression levels. Variation in protein 
expression levels could also cause a shift in subcellular localisation of visible eGFP signal and could 
underlie the possible retargeting effect of C-terminally eGFP-tagged wild type Densin-180 by mRFP-
tagged CaMKII-α observed.  
Western blot analysis of transfected cells would offer a means of quantifying protein expression 
levels as well as to check that expressed proteins are of the correct size, and therefore that the 
correct protein is being expressed. Such an approach would offer a means of testing whether or not 
the effects observed are due to structure-function relationship of Densin-180, or to variation in 
protein expression levels, or to unexpected post-translational modification of expressed protein.  
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eGFP-tag may have altered subcellular behaviour of Densin-180 
Since human Densin-180 was used as a starting point for engineering the constructs presented here, 
and since there were no anti-human Densin-180 antibody available at the time of experimentation, 
it was effectively impossible to check whether the introduction of the eGFP-tag caused any 
alteration to the normal localisation of Densin-180 in HEK cells. However, since anti-mouse Densin-
180 antibody was available, Dr Agnes Thalhammer was able to show that, in mouse primary 
hippocampal neuron cultures, the subcellular localisation of native Densin-180 matches that of N-
terminally eGFP-tagged Densin-180, pRK7a-N-eGFP-hLrrc7-WT, expressed in the same type of 
culture.  
TTT865/868/869AAA phosphomutants and phosphorich region truncation constructs 
The introduction of TTT865/868/869AAA phospho-null mutations caused an inhibition of puncta 
formation in both N-terminally and C-terminally eGFP-tagged Densin-180 (figure 2-3). As mentioned 
earlier, this triple phospho-null mutation is located right in the middle of Densin-180’s 
phosphorylation rich region. No experiments were carried out to elucidate the subcellular behaviour 
of the phospho-rich region truncation constructs presented in this thesis. A bioinformatic motif scan, 
searching for phosphosites, matched a number of kinases to known phosphorylation sites in the 
truncated portion of the phospho-rich region truncation constructs (table 3-1).  
Site Score Percentile Sequence SA Kinase 
T865 0.5319  0.00525 FPSKLETTPTTSPLP 2.662 GSK3 Kinase 
S869 0.5323  0.0053 LETTPTTSPLPERKE 1.261 GSK3 Kinase 
S869 0.4888  0.00369 LETTPTTSPLPERKE 1.261 Erk1 Kinase 
S949 0.326 0.00023 NKFKKSQSIDEIDIG 1.445 PKC epsilon 
S949 0.4359  0.00163 NKFKKSQSIDEIDIG 1.445 Calmodulin dependent Kinase 2 
S1118 0.5708  0.00696 GFLRRADSLVSATEM 0.425 Akt Kinase 
S1118 0.6282  0.00874 GFLRRADSLVSATEM 0.425 AMP_Kinase 
S1209 0.5558  0.0025 ARSYSTESYGASQTR 1.202 PDK1 Binding 
S1213 0.5082  0.00602 STESYGASQTRPVSA 1.503 DNA PK 
 
Table 3-1. Motif scan results: Q96NW7 (human Densin-180). Showing predicted kinase interactions 
at known phosphorylation sites within truncation of phospho-rich region truncation constructs. 
Motifs scanned: All. Stringency: Medium. http://scansite.mit.edu/motifscan_id.phtml 
The predicted involvement of the kinases, listed in table 3-1, which have roles in a wide array of cell 
functions which include cell survival, metabolism, Wnt signalling and LTP mediation, suggests that 
Densin-180 may have a role in the regulation of synaptic signalling in the central nervous system, 
with many parallels to the role played by Erbin in the regulation of NRG1 signalling and myelination 
in the peripheral nervous system [56]. Although the predicted involvement of GSK3 Kinase should be 
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taken note of, it should, however, be observed that since GSK3 kinase is not natively expressed in 
HEK cells, that effects seen in HEK cells expressing TTT865/868/869AAA variants may be due to 
changes in protein structure.  
The phosphorich region truncation constructs offer tools of great value for the future exploration of 
such a hypothesis. This sort of study may involve experiments similar to those presented here, as 
well as electrophysiological measurements. The study of Densin-180’s function in the regulation of 
neuronal cytoarchitecture in synaptic plasticity, in glomerular podocytes [52][53] and in Sertoli cells 
[54] could establish this protein as a pharmaceutical target for the synthetic regulation of learning 
and memory, kidney function [52][53] and for the development of a male contraception pill [54]. 
Such research will deserve careful and stringent review; their applications appropriate restriction.   
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Appendix 
Digests 
1. N-tag 
  
1.1 PCR 3 shuffle into intermediate cloning vector 
 
Preparative: PCR3 product / SacI /BglII
Component µl
DNA 15
NEBuffer 2 2.5
BSA 2
Enzyme A BglII 0.75
Enzyme B SacI 1
H2O 3.75
Total 25
 
 
 
Preparative: pRSET6a-Ca-His / SacI / BglII
Component µl
DNA 2
NEBuffer 2 2
BSA 2
Enzyme A BglII 0.75
Enzyme B SacI 1
H2O 17.25
Total 25
 
 
 
84 
Analytical: hLrrc7-pRSET6a-eGFP-PCR3 / BsrGI / SacII
Component µl
DNA 1.5
NEBuffer 3 1.5
BSA 1.5
Enzyme A BsrGI 0.5
Enzyme B SacII 0.5
H2O 9.5
Total 15  
 
 
  
85 
1.2 PCR4 shuffle into intermediate cloning construct 
 
Component µl
DNA 1.3
NEBuffer 3 1
BSA 0
Enzyme A BglII 0.5
Enzyme B NcoI 0.5
H2O 6.7
Total 10
Preparative: hLrrc7-pRSET6a-eGFP-PCR3 / 
BglII / NcoI
 
 
Preparative: PCR4 product / BamHI / NcoI
Component µl
DNA 1.3
NEBuffer 3 1
BSA 0
Enzyme A BglII 0.5
Enzyme B NcoI 0.5
H2O 6.7
Total 10  
 
 
 
Analytical: hLrrc7-pRSET6a-eGFP-PCR3-PCR4 /AccI
Component µl
DNA 1.5
NEBuffer 4 1.5
BSA 0
Enzyme A AccI 0.5
Enzyme B 0
H2O 11.5
Total 15  
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1.3 Shuffling eGFP-tagged Densin-180 N-terminus coding sequence into Densin-180 
construct 
 
Component µl
DNA 0.7
NEBuffer 3 1
BSA 1
Enzyme A NotI 0.5
Enzyme B XhoI 0.5
H2O 6.3
Total 10
 Preparative: hLrrc7-pRSET6a-eGFP-PCR3-PCR4 / NotI / 
XhoI 
 
 
Preparative: KS+-hLrrc7-unrepaired / NotI / XhoI
Component µl
DNA 0.7
NEBuffer 3 1
BSA 1
Enzyme A NotI 0.5
Enzyme B XhoI 0.5
H2O 6.3
Total 10  
 
 
 
Component µl
DNA 1.5
NEBuffer 4 1
BSA 1
Enzyme A AflII 0.5
Enzyme B AvrII 0.5
H2O 5.5
Total 10
Analytical: KS+-N-eGFP-hLrrc7-unrepaired / AvrII / AflII
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2. C-tag 
 
2.1 Shuffling tagged C-terminus into Densin-180 construct 
 
Preparative: KS+-hLrrc7-unrepaired / KpnI / SmaI
Component µl
DNA 6.66
NEBuffer 3 1
BSA 1
Enzyme A NotI 0.5
Enzyme B XhoI 0.5
H2O 0.34
Total 10  
 
Preparative: PCR3' product / KpnI / SmaI
Component µl
DNA 6.66
NEBuffer 3 1
BSA 1
Enzyme A NotI 0.5
Enzyme B XhoI 0.5
H2O 0.34
Total 10  
 
 
Analytical:  KS+-hLrrc7-eGFP-C-WT-unrepaired / EcoRI
Component µl
DNA 6.66
NEBuffer 3 1
BSA 1
Enzyme A NotI 0.5
Enzyme B XhoI 0.5
H2O 0.34
Total 10  
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3. Repair of construct and insertion of mutations 
  
3.1 Insertion repair fragment - PCR2 (Nested) product by AGT 
 
Preparative: PCR2 (nested) product / BlnI (AvrII) / AflII
Component µl
DNA 15
NEBuffer 4 2
BSA 2
Enzyme A BlnI 0.5
Enzyme B AflII 0.5
H2O 0
Total 20  
 
Component µl
DNA 15
NEBuffer 4 2
BSA 2
Enzyme A BlnI 0.5
Enzyme B AflII 0.5
H2O 0
Total 20
Preparative: [KS+-N-eGFP-hLrrc7-WT-unrepaired / KS+-
hLrrc7-eGFP-C-WT-unrepaired / BlnI (AvrII) / AflII
 
 
Analytical: KS+-N-eGFP-hLrrc7-WT-FULL / EcoRV
Component µl
DNA 1
NEBuffer 3 1
BSA 1
Enzyme A EcoRV 0.5
Enzyme B 0
H2O 6.5
Total 10  
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3.2 Inserting TTT865/868/869AAA mutation containing fragment 
 
Preparative: KS+-hLrrc7-eGFP-C-WT-FULL / AflII / ClaI   
Component µl
DNA 2
NEBuffer 4 1.5
BSA 1.5
Enzyme A ClaI 0.5
Enzyme B AflII 0.5
H2O 9
Total 15  
 
Preparative: KS+-N-eGFP-hLrrc7-TTT-unrepaired / AflII / ClaI
Component µl
DNA 5
NEBuffer 4 1.5
BSA 1.5
Enzyme A ClaI 0.5
Enzyme B AflII 0.5
H2O 6
Total 15  
 
Preparative: KS+-N-eGFP-hLrrc7-TTT-FULL or KS+-hLrrc7-eGFP-C-TTT-FULL / EcoRV
Component µl
DNA 1
NEBuffer 3 1.5
BSA 1.5
Enzyme A EcoRV 0.5
Enzyme B 0
H2O 10.5
Total 15  
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4. pRK7 vector modification and construct shuffle 
 
4.1 Vector modification 
 
Preparative: pRK7 / HindIII / SalI
Component µl
DNA 2.5
SalI Buffer 1.5
BSA 1.5
Enzyme A HindIII 0.5
Enzyme B SalI 0.5
H2O 8.5
Total 15  
2009-07-27 
 
Analytical: pRK7a / ScaI / XhoI
Component µl
DNA 1
NEBuffer 3 1.5
BSA 1.5
Enzyme A HindIII 0.5
Enzyme B SalI 0.5
H2O 10
Total 15  
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4.2 Shuffling the Densin-180 constructs from KS+, cloning vector, and into pRK7a, 
expression vector 
 
Preparative: pRK7a / NotI / KpnI
Component µl
DNA 8
NEBuffer 2 5
BSA 5
Enzyme A NotI 2
Enzyme B KpnI 2
H2O 28
Total 50  
 
Preparative: KS+-N-eGFP-hLrrc7-TTTorWT-FULL / NotI / KpnI
Component µl
DNA 8
NEBuffer 2 5
BSA 5
Enzyme A NotI 2
Enzyme B KpnI 2
H2O 28
Total 50  
 
Analytical : pRK7a-N-eGFP-hLrrc7-TTTorWT-FULL / ScaI / ClaI
Component µl
DNA 1
NEBuffer 2 1.5
BSA 1.5
Enzyme A ScaI 0.5
Enzyme B ClaI 0.5
H2O 10
Total 15  
 
 
Preparative: KS+-hLrrc7-eGFP-C-TTTorWT-FULL / NotI / KpnI
Component µl
DNA 2
NEBuffer 2 1.5
BSA 1.5
Enzyme A NotI 0.5
Enzyme B KpnI 0.66
H2O 8.34
Total 14.5  
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Analytical: pRK7a-hLrrc7-eGFP-C-TTTorWT-FULL / ScaI / ClaI
Component µl
DNA 1
NEBuffer 3 1.5
BSA 1.5
Enzyme A ScaI 0.25
Enzyme B ClaI 0.25
H2O 10.5
Total 15  
 
 
 
Analytical: pRK7a-hLrrc7-eGFP-C-TTT-FULL / PstI
Component µl
DNA 1
NEBuffer 3 1.5
BSA 1.5
Enzyme A PstI 0.5
Enzyme B
H2O 10.5
Total 15  
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5. PDZ truncation constructs 
 
Preparative: pRK7a-N-eGFP-hLrrc7-WT-FULL vs BamHI / BspEI
Component µl
DNA 1
NEBuffer 3 2
BSA 2
Enzyme A BamHI 0.5
Enzyme B BspEI 0.5
H2O 14
Total 20  
 
Preparative: PCR fragments A, B and C / BamHI / BspEI
Component µl
DNA 10
NEBuffer 3 2
BSA 2
Enzyme A BamHI 0.5
Enzyme B BspEI 0.5
H2O 5
Total 20  
 
Component µl
DNA 1
NEBuffer 4 2
BSA 2
Enzyme A HpaI 0.5
Enzyme B 0
H2O 14.5
Total 20
Analytical: PDZ deletion construct A, B and C / 
HpaI
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6. Phospho-rich region deletion constructs 
 
Component µl
DNA 1
NEBuffer 4 2
BSA 2
Enzyme A XmaI 0.5
Enzyme B - 0
H2O 14.5
Total 20
Preparative: pRK7a-N-eGFP-hLrrc7-WT / XmaI and pRK7a-
hLrrc7-eGFP-C-WT / XmaI
 
 
Analytical digest: pRK7a-hLrrc7-eGFP-C-WT-no phosphorich / XhoI
pRK7a-N-eGFP-hLrrc7-WT-FULL-no phosphorich / XhoI
Component µl
DNA 1
NEBuffer 4 2
BSA 2
Enzyme AXmaI 0.5
Enzyme B- 0
H2O 14.5
Total 20  
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Polymerase Chain Reactions 
 
1. KS+-N-eGFP-hLrrc7-WT 
 
PCR1
Reaction Mixture
Component µl
Template DNA KS+-hLrrc7-unrepaired, 1:100 miniprep DNA in H2O 1
Sense Primer KSpIMCS-Seq1-s, 10µM 2 0.4 µM
Anti-sense primer EGFP-hLrrc7-PCR1-a, 10µM 2 0.4 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl2 2 1 mM
2.5 U/µl KOD Polymerase 0.2 0.010 U/µl
5 mM dNTP 2 0.2 mM
DMSO 0 0 %
H2O 35.8
50Total volume
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 60°C 30 sec
4 72°C 10 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
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PCR2 
 
Reaction Mixture
Component µl
Template DNA pBS.EGFP.MT.CK2a, 1:100 miniprep DNA 1
Sense Primer EGFP-hLrrc7-PCR2-s, 10µM 2 0.4 µM
Anti-sense primer EGFP-PCR2-a, 10µM 2 0.4 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl2 2 1 mM
2.5 U/µl KOD Polymerase 0.2 0.010 U/µl
5 mM dNTP 2 0.2 mM
DMSO 0 0 %
H2O 35.8
50Total volume
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 70°C 30 sec
4 72°C 10 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
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PCR3 
 
Reaction Mixture
Component µl
Template DNA 1 Product of PCR1 1
Template DNA 2 Product of PCR2 1
Sense Primer KSpIMCS-Seq1-s, 10µM 1 0.5 µM
Anti-sense primer EGFP-PCR2-a, 10µM 1 0.5 µM
10x KOD Polymerase buffer 2.5 1.25 X
25 mM MgCl2 1 1.25 mM
2.5 U/µl KOD Polymerase 0.1 0.013 U/µl
5 mM dNTP 1 0.25 mM
DMSO 0 0 %
H2O 11.4
20Total volume
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 60°C 30 sec
4 72°C 10 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------
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PCR4 
 
Reaction Mixture
Component µl
Template DNA 1 KS+-hLrrc7-unrepaired, 1:100 miniprep DNA 1
Sense Primer hLrrc7-PCR1-s, 10µM 1 0.2 µM
Anti-sense primer hLrrc7-Seq11-a, 10µM 1 0.2 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl2 2 1 mM
2.5 U/µl KOD Polymerase 0.25 0.013 U/µl
5 mM dNTP 4 0.4 mM
DMSO 0 0 %
H2O 35.75
50Total volume
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 50°C 30 sec
4 72°C 15 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
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2. KS+-hLrrc7-eGFP-C-WT 
 
PCR1’ 
 
Reaction Mixture
Component µl
Template DNA 1 KS+-hLrrc7-unrepaired, 1:100 miniprep DNA 1
Sense Primer hLrrc7-Seq6-s, 10µM 2 0.4 µM
Anti-sense primer EGFP-hLrrc7-PCR4-a, 10µM 2 0.4 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl2 2 1 mM
2.5 U/µl KOD Polymerase 0.25 0.013 U/µl
5 mM dNTP 2 0.2 mM
DMSO 0 0 %
H2O 35.75
50Total volume
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 50°C 30 sec
4 72°C 30 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
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PCR2’ 
 
Reaction Mixture
Component µl
Template DNA 1 pBS.EGFP.MT.CK2a, 1:100 miniprep DNA 1
Sense Primer EGFP-hLrrc7-PCR3-s, 10µM 2 0.4 µM
Anti-sense primer EGFP-PCR8-a, 10µM 2 0.4 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl2 2 1 mM
2.5 U/µl KOD Polymerase 0.25 0.013 U/µl
5 mM dNTP 2 0.2 mM
DMSO 0 0 %
H2O 35.75
50Total volume
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 70°C 30 sec
4 72°C 10 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
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PCR3’ 
 
Reaction Mixture
Component µl
Template DNA 1 Product of PCR1' 1
Template DNA 2 Product of PCR2' 2
Sense Primer hLrrc7-Seq6-s, 10µM 1 0.2 µM
Anti-sense primer EGFP-PCR8-a, 10µM 1 0.2 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl2 1 0.5 mM
2.5 U/µl KOD Polymerase 0.5 0.025 U/µl
2 mM dNTP 5 0.2 mM
DMSO 0 0 %
H2O 33.5
50Total volume
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 56°C 30 sec
4 72°C 15 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
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3.  PDZ truncations 
 
PCR A 
 
Reaction Mixture
Component µl
Template pRK7a-N-eGFP-hLrrc7-WT / SacII Phenol/Chloroform purified1
Sense Primer (10µM) hLrrc7-Seq6-s 2 0.4 µM
Anti-sense primer (10µM) hLrrc7-PCR11-a 2 0.4 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl 2 3 1.5 mM
2.5 U/µl KOD Polymerase 0.5 0.025 U/µl
2 mM dNTP 5 0.2 mM
DMSO 0 0 %
H2O 31.5
Total volume excluding DNA
Final total volume 50
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 55°C 30 sec
4 72°C 10 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
PCR B 
 
Reaction Mixture
Component µl
Template pRK7a-N-eGFP-hLrrc7-WT / SacII Phenol/Chloroform purified1
Sense Primer (10µM) hLrrc7-Seq6-s 2 0.4 µM
Anti-sense primer (10µM) hLrrc7-PCR12-a 2 0.4 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl 2 3 1.5 mM
2.5 U/µl KOD Polymerase 0.5 0.025 U/µl
2 mM dNTP 5 0.2 mM
DMSO 0 0 %
H2O 31.5
Total volume excluding DNA
Final total volume 50
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 55°C 30 sec
4 72°C 10 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
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PCR C 
 
Reaction Mixture
Component µl
Template pRK7a-N-eGFP-hLrrc7-WT / SacII Phenol/Chloroform purified1
Sense Primer (10µM) hLrrc7-Seq6-s 2 0.4 µM
Anti-sense primer (10µM) hLrrc7-PCR13-a 2 0.4 µM
10x KOD Polymerase buffer 5 1 X
25 mM MgCl2 3 1.5 mM
2.5 U/µl KOD Polymerase 0.5 0.025 U/µl
2 mM dNTP 5 0.2 mM
DMSO 0 0 %
H2O 31.5
Total volume excluding DNA
Final total volume 50
Final concentration
 
 
PCR Cycle
Step
1 95°C 5 min
2 95°C 30 sec
3 55°C 30 sec
4 72°C 10 sec Repeat steps 2 - 4 for 29 cycles
5 10°C pause  
------------------------------------------------------------------------------------------------------------ 
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DNA sequences 
 
Primers 
 
KSpIMCS-Seq1-s 
ACTCACTATAGGGCGAATTGGAGCTCCAC 
 
EGFP-hLrrc7-PCR1-a 
tcgcccttgctcaccatACTGCAGTGGGAGTAATCT 
 
EGFP-hLrrc7-PCR2-s 
AGATTACTCCCACTGCAGTatggtgagcaagggcgaggagctg 
 
EGFP-PCR2-a (by CET) 
cgccggtaccgctagcgatatcagatctgagCTTGTACAGCTCGTCCATG 
CCGAG 
 
hLrrc7-PCR1-s 
cgggatccCTTCAGCAGGTGCCAAAGGAGGTC 
 
hLrrc7-Seq11-a 
TACCAATGTCAATCTCATCG 
 
hLrrc7-Seq6-s 
AAGCTACAGTACAGAGAG 
 
EGFP-hLrrc7-PCR4-a 
cagctcctcgcccttgctcaccatGACAGTAAGCTCACGTTGAATAAC 
 
EGFP-hLrrc7-PCR3-s 
GTTATTCAACGTGAGCTTACTGTCatggtgagcaagggcgaggagctg 
 
EGFP-PCR8-a 
cgccggtaccTTACTTGTACAGCTCGTCCATGCCGAG 
 
hLrrc7-PCR11-a 
ATGggatccTTAGACAGTAAGCTCACGTTGTGGATATCCATCCATACTCC 
 
hLrrc7-PCR12-a 
ATGATGggatccTTATGGATATCCATCCATACTCCT 
 
hLrrc7-PCR13-a 
ATGATGggatccTTACTCACGTTGAATAACTAGGTC 
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Amino acid sequence alignments 
Whole sequence alignment 
 
Q80TE7 LRRC7_MOUSE 
P70587 LRRC7_RAT 
Q96NW7 LRRC7_HUMAN 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
 
Q80TE7          -----MTTKRKLIGRLVPCRCFRGEEEIISVLDYSHCSLQQVPKEVFNFERTLEELYLDA 55 
P70587          MQCLEMTTKRKLIGRLVPCRCFRGEEEIISVLDYSHCSLQQVPKEVFNFERTLEELYLDA 60 
Q96NW7          -----MTTKRKIIGRLVPCRCFRGEEEIISVLDYSHCSLQQVPKEVFNFERTLEELYLDA 55 
                     ******:************************************************ 
 
Q80TE7          NQIEELPKQLFNCQALRKLSIPDNDLSSLPTSIASLVNLKELDISKNGVQEFPENIKCCK 115 
P70587          NQIEELPKQLFNCQALRKLSIPDNDLSSLPTSIASLVNLKELDISKNGVQEFPENIKCCK 120 
Q96NW7          NQIEELPKQLFNCQALRKLSIPDNDLSNLPTTIASLVNLKELDISKNGVQEFPENIKCCK 115 
                ***************************.***:**************************** 
 
Q80TE7          CLTIIEASVNPISKLPDGFTQLLNLTQLYLNDAFLEFLPANFGRLVKLRILELRENHLKT 175 
P70587          CLTIIEASVNPISKLPDGFTQLLNLTQLYLNDAFLEFLPANFGRLVKLRILELRENHLKT 180 
Q96NW7          CLTIIEASVNPISKLPDGFTQLLNLTQLYLNDAFLEFLPANFGRLVKLRILELRENHLKT 175 
                ************************************************************ 
 
Q80TE7          LPKSMHKLAQLERLDLGNNEFSELPEVLDQIQNLRELWMDNNALQVLPGSIGKLKMLVYL 235 
P70587          LPKSMHKLAQLERLDLGNNEFSELPEVLDQIQNLRELWMDNNALQVLPGSIGKLKMLVYL 240 
Q96NW7          LPKSMHKLAQLERLDLGNNEFGELPEVLDQIQNLRELWMDNNALQVLPGSIGKLKMLVYL 235 
                *********************.************************************** 
 
Q80TE7          DMSKNRIETVDMDISGCEALEDLLLSSNMLQQLPDSIGLLKKLTTLKVDDNQLTMLPNTI 295 
P70587          DMSKNRIETVDMDISGCEALEDLLLSSNMLQQLPDSIGLLKKLTTLKVDDNQLTMLPNTI 300 
Q96NW7          DMSKNRIETVDMDISGCEALEDLLLSSNMLQQLPDSIGLLKKLTTLKVDDNQLTMLPNTI 295 
                ************************************************************ 
 
Q80TE7          GNLSLLEEFDCSCNELESLPPTIGYLHSLRTLAVDENFLPELPREIGSCKNVTVMSLRSN 355 
P70587          GNLSLLEEFDCSCNELESLPPTIGYLHSLRTLAVDENFLPELPREIGSCKNVTVMSLRSN 360 
Q96NW7          GNLSLLEEFDCSCNELESLPSTIGYLHSLRTLAVDENFLPELPREIGSCKNVTVMSLRSN 355 
                ********************.*************************************** 
 
Q80TE7          KLEFLPEEIGQMQRLRVLNLSDNRLKNLPFSFTKLKELAALWLSDNQSKALIPLQTEAHP 415 
P70587          KLEFLPEEIGQMQRLRVLNLSDNRLKNLPFSFTKLKELAALWLSDNQSKALIPLQTEAHP 420 
Q96NW7          KLEFLPEEIGQMQKLRVLNLSDNRLKNLPFSFTKLKELAALWLSDNQSKALIPLQTEAHP 415 
                *************:********************************************** 
 
Q80TE7          ETKQRVLTNYMFPQQPRGDEDFQSDSDSFNPTLWEEQRQQRMTVAFEFEDKKEDDESAGK 475 
P70587          ETKQRVLTNYMFPQQPRGDEDFQSDSDSFNPTLWEEQRQQRMTVAFEFEDKKEDDESAGK 480 
Q96NW7          ETKQRVLTNYMFPQQPRGDEDFQSDSDSFNPTLWEEQRQQRMTVAFEFEDKKEDDENAGK 475 
                ********************************************************.*** 
 
Q80TE7          VKALSCQAPWDRGQRGITLQPARLSGDCCTPWARCDQQIQDMPVPQSDPQLAWGCISGLQ 535 
P70587          VKALSCQAPWDRGQRGITLQPARLSGDCCTPWARCDQQIQDMPVPQSDPQLAWGCISGLQ 540 
Q96NW7          VKDLSCQAPWERGQRGITLQPARLSGDCCTPWARCDQQIQDMPVPQNDPQLAWGCISGLQ 535 
                ** *******:***********************************.************* 
 
Q80TE7          QERSMCAPLPVAAQSTTLPSLSGRQVEINLKRYPTPYPEDLKNMVKSVQNLVGKPSHGVR 595 
P70587          QERSMCAPLPVAAQSTTLPSLSGRQVEINLKRYPTPYPEDLKNMVKSVQNLVGKPSHGVR 600 
Q96NW7          QERSMCTPLPVAAQSTTLPSLSGRQVEINLKRYPTPYPEDLKNMVKSVQNLVGKPSHGVR 595 
                ******:***************************************************** 
 
Q80TE7          VENSNPTANTEQTVKEKFEHKWPVAPKEITVEDSFVHPANEMRIGELHPSLAETPLYPPK 655 
P70587          VENANPTANTEQTVKEKFEHKWPVAPKEITVEDSFVHPANEMRIGELHPSLAETPLYPPK 660 
Q96NW7          VENSNPTANTEQTVKEKYEHKWPVAPKEITVEDSFVHPANEMRIGELHPSLAETPLYPPK 655 
                ***:*************:****************************************** 
 
Q80TE7          LVLLGKDKKESTDESEVDKTHCLNNSVSSGTYSDYSPSQASSASSNTRMKVGSLQATAKD 715 
P70587          LVLLGKDKKESTDESEVDKTHCLNNSVSSGTYSDYSPSQASSASSNTRVKVGSLQPTTKD 720 
Q96NW7          LVLLGKDKKESTDESEVDKTHCLNNSVSSGTYSDYSPSQASSGSSNTRVKVGSLQTTAKD 715 
                ******************************************.*****:******.*:** 
 
Q80TE7          AVHNSLWGNRIAPPFPQPLDAKPLLSQREAVPPGNIPQRPDRLPMSDAFPDNWTDGSHYD 775 
P70587          AVHNSLWGNRIAPPFPQPLDAKPLLTQREAVPPGNLPQRPDRLPMSDAFPDNWTDGSHYD 780 
Q96NW7          AVHNSLWGNRIAPSFPQPLDSKPLLSQREAVPPGNIPQRPDRLPMSDTFTDNWTDGSHYD 775 
                *************.******:****:*********:***********:*.********** 
106 
 
Q80TE7          NTGFVSEEAAGENANNNPLLSSKARSVPAHGRRPLIRQERIVGVPLELEQSTHRHTPETE 835 
P70587          NTGFVSEEATGENANNNPLLSSKARSVPAHGRRPLIRQERIVGVPLELEQSTHRHTPETE 840 
Q96NW7          NTGFVAEETTAENANSNPLLSSKSRSTSSHGRRPLIRQDRIVGVPLELEQSTHRHTPETE 835 
                *****:**::.****.*******:**..:*********:********************* 
 
Q80TE7          VPPSNPWQNWTRTPSPFEDRTAFPSKLETTPTTSPLPERKDHMKEPTETPGPFSPGVPWE 895 
P70587          VPPSNPWQNWTRTPSPFEDRTAFPSKLETTPTTSPLPERKDHMKEPTETPGPFSPGVPWE 900 
Q96NW7          VPPSNPWQNWTRTPSPFEDRTAFPSKLETTPTTSPLPERKEHIKESTEIPSPFSPGVPWE 895 
                ****************************************:*:**.** *.********* 
 
Q80TE7          YHDPTPNRSLGNVFSQIHCRPDSSKGVIAISKSTERLSPLMKDIKSNKFKKSQSIDEIDV 955 
P70587          YHDPTPNRSLGNVFSQIHCRPDSSKGVIAISKSTERLSPLMKDIKSNKFKKSQSIDEIDV 960 
Q96NW7          YHDSNPNRSLSNVFSQIHCRPESSKGVISISKSTERLSPLMKDIKSNKFKKSQSIDEIDI 955 
                ***..*****.**********:******:******************************: 
 
Q80TE7          GTYKVYNIPLENYASGSDHLGSHERPDKFLGPEHGMSSMSRSQSVPMLDDEMLMYGSSKG 1015 
P70587          GTYKVYNIPLENYASGSDHLGSHERPDKFLGPEHGMSSMSRSQSVPMLDDEMLMYGSSKG 1020 
Q96NW7          GTYKVYNIPLENYASGSDHLGSHERPDKMLGPEHGMSSMSRSQSVPMLDDEMLTYGSSKG 1015 
                ****************************:************************ ****** 
 
Q80TE7          PPQQKASMTKKVYQFDQSFNPQGAVEVKAEKRIPPPFAHNSEYVQQPSKNIAKDLVSPRA 1075 
P70587          PPQQKASMTKKVYQFDQSFNPQGAVEVKAEKRIPPPFAHNSEYVQQPGKNIAKDLVSPRA 1080 
Q96NW7          PQQQKASMTKKVYQFDQSFNPQGSVEVKAEKRIPPPFQHNPEYVQQASKNIAKDLISPRA 1075 
                * *********************:************* **.*****..*******:**** 
 
Q80TE7          YRGYPPMEQMFSFSQPSVNEDAMVNAQFASQGPRAGFLRRADSLASSTEMAMFRRVSEPH 1135 
P70587          YRGYPPMEQMFSFSQPSVNEDAMVNAQFASQGPRAGFLRRADSLASSTEMAMFRRVSEPH 1140 
Q96NW7          YRGYPPMEQMFSFSQPSVNEDAVVNAQFASQGARAGFLRRADSLVSATEMAMFRRVNEPH 1135 
                **********************:*********.***********.*:*********.*** 
 
Q80TE7          ELPPGDRYGRATYRGGLEGQSSISMTDPQFLKRNGRYEDEHPSYQEVKAQAGSFPAKNLT 1195 
P70587          ELPPGDRYGRAAYRGGLEGQSSVSMTDPQFLKRNGRYEDEHPSYQEVKAQAGSFPAKNLT 1200 
Q96NW7          ELPPTDRYGRPPYRGGLDRQSSVTVTESQFLKRNGRYEDEHPSYQEVKAQAGSFPVKNLT 1195 
                **** *****..*****: ***:::*:.***************************.**** 
 
Q80TE7          QRRPLSARSYSTESYGASQTRPVSARPTMAALLEKIPSDYNLGNYGDKTSDNSDIKTRPT 1255 
P70587          QRRPLSARSYSTESYGASQTRPVSARPTMAALLEKIPSDYNLGNYGDKTSDNSDIKTRPT 1260 
Q96NW7          QRRPLSARSYSTESYGASQTRPVSARPTMAALLEKIPSDYNLGNYGDKPSDNSDLKTRPT 1255 
                ************************************************.*****:***** 
 
Q80TE7          PVKGEESCGKMPADWRQQLLRHIEARRLDR------------------------------ 1285 
P70587          PVKGEESCGKMPADWRQQLLRHIEARRLDR------------------------------ 1290 
Q96NW7          PVKGEESCGKMPADWRQQLLRHIEARRLDRNAAYKHNTVNLGMLPYGGISAMHAGRSMTL 1315 
                ******************************                               
 
Q80TE7          -----------------TPSQQSNILDNGQEDVSPSGQWNPYPLGRRDVPPDTITKKAGS 1328 
P70587          -----------------TPSQQSNILDNGQEDVSPSGQWNPYPLGRRDVPPDTITKKAGS 1333 
Q96NW7          NLQTKSKFDHQELPLQKTPSQQSNILDNGQEDVSPSGQWNPYPLGRRDVPPDTITKKAGS 1375 
                                 ******************************************* 
 
Q80TE7          HIQTLMGSQSLQHRSREQQPYEGNINKVTIQQFQSPLPIQIPSSQATRGPQPGRCLIQTK 1388 
P70587          HIQTLMGSQSLQHRSREQQPYEGNINKVTIQQFQSPLPIQIPSSQATRGPQPGRCLIQTK 1393 
Q96NW7          HIQTLMGSQSLQHRSREQQPYEGNINKVTIQQFQSPLPIQIPSSQATRGPQPGRCLIQTK 1435 
                ************************************************************ 
 
Q80TE7          GQRSMDGYPEQFCVRIEKNPGLGFSISGGISGQGNPFKPSDKGIFVTRVQPDGPASNLLQ 1448 
P70587          GQRSMDGYPEQFCVRIEKNPGLGFSISGGISGQGNPFKPSDKGIFVTRVQPDGPASNLLQ 1453 
Q96NW7          GQRSMDGYPEQFCVRIEKNPGLGFSISGGISGQGNPFKPSDKGIFVTRVQPDGPASNLLQ 1495 
                ************************************************************ 
 
Q80TE7          PGDKILQANGHSFVHMEHEKAVLLLKSFQNTVDLVIQRELTV 1490 
P70587          PGDKILQANGHSFVHMEHEKAVLLLKSFQNTVDLVIQRELTV 1495 
Q96NW7          PGDKILQANGHSFVHMEHEKAVLLLKSFQNTVDLVIQRELTV 1537 
                ****************************************** 
 
 
Mouse (Q80TE7) vs Rat (P70587): 99% 
Mouse (Q80TE7) vs Human (Q96NW7): 92% 
 
 
---------------------- 
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Phosphorich region (aa 826 to aa 1213) 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
 
mouse           -----STHRHTPETEVPPSNPWQNWTRTPSPFEDRTAFPSKLETTPTTSPLPERKDHMKE 55 
rat             LELEQSTHRHTPETEVPPSNPWQNWTRTPSPFEDRTAFPSKLETTPTTSPLPERKDHMKE 60 
human           -----STHRHTPETEVPPSNPWQNWTRTPSPFEDRTAFPSKLETTPTTSPLPERKEHIKE 55 
                     **************************************************:*:** 
 
mouse           PTETPGPFSPGVPWEYHDPTPNRSLGNVFSQIHCRPDSSKGVIAISKSTERLSPLMKDIK 115 
rat             PTETPGPFSPGVPWEYHDPTPNRSLGNVFSQIHCRPDSSKGVIAISKSTERLSPLMKDIK 120 
human           STEIPSPFSPGVPWEYHDSNPNRSLSNVFSQIHCRPESSKGVISISKSTERLSPLMKDIK 115 
                .** *.************..*****.**********:******:**************** 
 
mouse           SNKFKKSQSIDEIDVGTYKVYNIPLENYASGSDHLGSHERPDKFLGPEHGMSSMSRSQSV 175 
rat             SNKFKKSQSIDEIDVGTYKVYNIPLENYASGSDHLGSHERPDKFLGPEHGMSSMSRSQSV 180 
human           SNKFKKSQSIDEIDIGTYKVYNIPLENYASGSDHLGSHERPDKMLGPEHGMSSMSRSQSV 175 
                **************:****************************:**************** 
 
mouse           PMLDDEMLMYGSSKGPPQQKASMTKKVYQFDQSFNPQGAVEVKAEKRIPPPFAHNSEYVQ 235 
rat             PMLDDEMLMYGSSKGPPQQKASMTKKVYQFDQSFNPQGAVEVKAEKRIPPPFAHNSEYVQ 240 
human           PMLDDEMLTYGSSKGPQQQKASMTKKVYQFDQSFNPQGSVEVKAEKRIPPPFQHNPEYVQ 235 
                ******** ******* *********************:************* **.**** 
 
mouse           QPSKNIAKDLVSPRAYRGYPPMEQMFSFSQPSVNEDAMVNAQFASQGPRAGFLRRADSLA 295 
rat             QPGKNIAKDLVSPRAYRGYPPMEQMFSFSQPSVNEDAMVNAQFASQGPRAGFLRRADSLA 300 
human           QASKNIAKDLISPRAYRGYPPMEQMFSFSQPSVNEDAVVNAQFASQGARAGFLRRADSLV 295 
                *..*******:**************************:*********.***********. 
 
mouse           SSTEMAMFRRVSEPHELPPGDRYGRATYRGGLEGQSSISMTDPQFLKRNGRYEDEHPSYQ 355 
rat             SSTEMAMFRRVSEPHELPPGDRYGRAAYRGGLEGQSSVSMTDPQFLKRNGRYEDEHPSYQ 360 
human           SATEMAMFRRVNEPHELPPTDRYGRPPYRGGLDRQSSVTVTESQFLKRNGRYEDEHPSYQ 355 
                *:*********.******* *****..*****: ***:::*:.***************** 
 
mouse           EVKAQAGSFPAKNLTQRRPLSARSYSTESYGAS 388 
rat             EVKAQAGSFPAKNLTQRRPLSARSYSTE----- 388 
human           EVKAQAGSFPVKNLTQRRPLSARSYSTESYGAS 388 
                **********.*****************      
 
Sequence identity  
Rat vs mouse – 99% 
Rat vs human – 90% 
 
 
 
---------------------- 
 
108 
Rat Repair region 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
 
Rat             DLGNNEFSELPEVLDQIQNLRELWMDNNALQVLPGSIGKLKMLVYLDMSKNRIETVDMDI 60 
Human           DLGNNEFGELPEVLDQIQNLRELWMDNNALQVLPGSIGKLKMLVYLDMSKNRIETVDMDI 60 
                *******.**************************************************** 
 
Rat             SGCEALEDLLLSSNMLQQLPDSIGLLKKLTTLKVDDNQLTMLPNTIGNLSLLEEFDCSCN 120 
Human           SGCEALEDLLLSSNMLQQLPDSIGLLKKLTTLKVDDNQLTMLPNTIGNLSLLEEFDCSCN 120 
                ************************************************************ 
 
Rat             ELESLPPTIGYLHSLRTLAVDENFLPELPREIGSCKNVTVMSLRSNKLEFLPEEIGQMQR 180 
Human           ELESLPSTIGYLHSLRTLAVDENFLPELPREIGSCKNVTVMSLRSNKLEFLPEEIGQMQK 180 
                ******.****************************************************: 
 
Rat             LRVLNLSDNRLKNLPFSFTKLKELAALWLSDNQSKALIPLQTEAHPETKQRVLTNYMFPQ 240 
Human           LRVLNLSDNRLKNLPFSFTKLKELAALWLSDNQSKALIPLQTEAHPETKQRVLTNYMFPQ 240 
                ************************************************************ 
 
Rat             QPRGDEDFQSDSDSFNPTLWEEQRQQRMTVAFEFEDKKEDDESAGKVKALSCQAPWDRGQ 300 
Human           QPRGDEDFQSDSDSFNPTLWEEQRQQRMTVAFEFEDKKEDDENAGKVKDLSCQAPWERGQ 300 
                ******************************************.***** *******:*** 
 
Rat             RGITLQPARLSGDCCTPWARCDQQIQDMPVPQSDPQLAWGCISGLQQERSMCAPLPVAAQ 360 
Human           RGITLQPARLSGDCCTPWARCDQQIQDMPVPQNDPQLAWGCISGLQQERSMCTPLPVAAQ 360 
                ********************************.*******************:******* 
 
Rat             STTLPSLSGRQVEINLKRYPTPYPEDLKNMVKSVQNLVGKPSHGVRVENANPTANTEQTV 420 
Human           STTLPSLSGRQVEINLKRYPTPYPEDLKNMVKSVQNLVGKPSHGVRVENSNPTANTEQTV 420 
                *************************************************:********** 
 
Rat             KEKFEHKWP 429 
Human           KEKYEHKWP 429 
                ***:***** 
 
rat vs human: 97% 
 
 
